| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Sanofi$43.5
-0.32 (-0.74%)
A 87Pipeline Score Undervalued Pharma · Commercial
Market Cap
107.37 B
EPS
2.40
P/E Ratio
18.55 $
Value Trade
105.21 M
2.95 %
Week
-6.82 %
1 Month
-5.32 %
3 Month
-10.56 %
6 Month
-17.69 %
5 Year
45.21 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
2.66 M
52 Week Range
42.33 - 53.03
% held by Insiders
0 %
% held by Institutions
8.78 %
Enterprise Value
122.63 B
Total Shares
2.40 B
Short %
0.27 %
Float Shares
2.40 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sanofi
1452Total events
19Upcoming
813Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 19
Sep 1, 2026
T2Management Change
Appointment of Paulo Fontoura as Executive Vice President, Global Head of R&D Pharma
TBD
T2Oral Presentation
Data from AIRCULES, DUET, and VELVET to be presented at upcoming medical congresses
TBD
T2Oral Presentation
Results from COAST 1, COAST 2, SHORE, and ATLANTIS to be presented at forthcoming medical congresses
Event history 1433
Jul 10, 2026
▲FDA ApprovalFDA Decision
EU approval of Sarclisa SC (Sarclisa Escena) for multiple myeloma across all approved IV indications
multiple myelomasource ↗
Jul 10, 2026
▲Full ResultsClinical Data
IRAKLIA phase 3 results: non-inferiority of SC vs IV Sarclisa in combination with pomalidomide and dexamethasone
relapsed or refractory multiple myelomasource ↗
Jul 10, 2026
◆NDA SubmissionRegulatory Filing
Regulatory submission for CirCLIQ OBI in Japan under review
multiple myelomasource ↗
Jul 8, 2026
◆Oral PresentationNexviazymePresentation
Results to be presented at 19th International Congress on Neuromuscular Diseases
infantile-onset Pompe diseasesource ↗
Jul 5, 2026
◆PDUFA DateTzieldApprovedRegulatory Filing
Target action date for FDA decision on Tzield sBLA
stage 2 type 1 diabetessource ↗
Jun 30, 2026
▲Primary Endpoint MetNexviazymeClinical Data
Nexviazyme met primary endpoint in Baby-COMET study
infantile-onset Pompe diseasesource ↗
Jun 30, 2026
▲Secondary Endpoint DataNexviazymeClinical Data
All secondary endpoints met in Baby-COMET study
infantile-onset Pompe diseasesource ↗
Jun 23, 2026
▲Partnership / LicenseCorporate
Sanofi signs MoU with Abu Dhabi Department of Health to explore vaccine innovation center
Jun 23, 2026
▲EU ApprovalCenrifkiEx-US Regulatory
European Commission approval of Cenrifki for SPMS without relapses
secondary progressive multiple sclerosis without relapsessource ↗
Jun 23, 2026
▲CHMP Positive OpinionCenrifkiEx-US Regulatory
CHMP positive opinion for Cenrifki
secondary progressive multiple sclerosis without relapsessource ↗
Jun 23, 2026
▲Topline ReadoutTolebrutinibClinical Data
HERCULES phase 3 topline results supporting approval
non-relapsing secondary progressive multiple sclerosissource ↗
Jun 23, 2026
▲Other Regulator MilestoneWayrilzApprovedEx-US Regulatory
Wayrilz approved in Japan for ITP
immune thrombocytopeniasource ↗
Drug Pipeline Intelligence
A87
Pipeline Score $275.9B
Pipeline ValueUndervalued
Valuation Signal522
Drugs Scored4.4x
rNPV / MCap Top 99%
Large Pharma (rank 10 of 911)
Percentile RankSanofi earns an A-grade pipeline score (87/100), with $276.3B risk-adjusted pipeline value, led by teplizumab in Type 1 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| teplizumab Monoclonal antibody | Type 1 Diabetes Mellitus | Phase 3 | NCT03875729 | 61% | $15.8B | COMPLETED | 1,061 | - | - | Apr 1, 2023 | ELEVATED_RISK | Apr 23, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
venglustat BreakthroughPriorityFast Track+1 | type 3 Gaucher disease | Phase 3 | 2026-05-28 | adverse events: headache 14.3% in the venglustat arm versus 18.2% in the ERT arm, nausea 14.3% versus 4.5%, spleen enlargement 14.3% versus 0, diarrhea 14.3% versus 0 Read More | Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris Read More | |
venglustat BreakthroughPriorityFast Track+1 | type 3 Gaucher disease | Phase 3 | 2026-05-28 | adverse events: headache 14.3% in the venglustat arm versus 18.2% in the ERT arm, nausea 14.3% versus 4.5%, spleen enlargement 14.3% versus 0, diarrhea 14.3% versus 0 Read More | Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris Read More | |
venglustat BreakthroughPriorityFast Track+1 | type 3 Gaucher disease | Phase 3 | 2026-05-28 | adverse events: headache 14.3% in the venglustat arm versus 18.2% in the ERT arm, nausea 14.3% versus 4.5%, spleen enlargement 14.3% versus 0, diarrhea 14.3% versus 0 Read More | Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SNY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SNY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SNY▼ -0.7%today
Sanofi: Information concerning the total number of voting rights and shares - June 2026
Sanofi has released information regarding the total number of voting rights and shares as required by French regulations. The announcement includes details about the company's registered share capital and its registered office. This information is accessible on Sanofi's official website for investors.
Read more →SNY▼ -0.7%today
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi's Sarclisa Escena has received FDA approval as the first anticancer treatment to be administered via an on-body injector. This subcutaneous formulation is designed to enhance the treatment experience for patients with multiple myeloma, offering similar efficacy and safety as the intravenous version. The approval is based on the IRAKLIA phase 3 study, which showed comparable outcomes with a significantly reduced treatment time.
Read more →SNYPress Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi's Nexviazyme successfully met all primary and secondary endpoints in the Baby-COMET phase 3 study for infantile-onset Pompe disease. The study demonstrated that treatment-naïve infants aged six months and younger were alive and free of invasive ventilation after 52 weeks. Sanofi plans to submit these results for regulatory approval in the US later in 2026.
Read more →SNYPress Release: Sanofi Foundation opens new chapter centered on future generations
The Sanofi Foundation is launching a new initiative focused on supporting children and young people, particularly those with serious health challenges. This includes partnerships aimed at improving early diagnosis and care for conditions like cerebral palsy. The Foundation is also committing €15 million annually to enhance its programs and humanitarian efforts, aiming to benefit over 6 million young individuals by 2030.
Read more →SNYDas Gesundheitsministerium und Sanofi gehen Partnerschaft ein, um Innovationen im Bereich der Impfstoffe voranzutreiben
The Department of Health in Abu Dhabi and Sanofi have signed a memorandum to enhance vaccine innovation through a partnership. This collaboration aims to establish a vaccine innovation center, leveraging AI and mRNA research to improve public health. The initiative is part of Abu Dhabi's commitment to global health security and aims to foster local scientific talent and advanced manufacturing.
Read more →SNYPress Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz has been approved in Japan for the treatment of immune thrombocytopenia (ITP), based on positive results from the LUNA 3 phase 3 study. The drug, a BTK inhibitor, demonstrated significant improvements in platelet counts and other symptoms in patients. This approval offers a new therapeutic option for those who have not responded to existing treatments.
Read more →SNYPress Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) has been approved by the European Commission as the first treatment specifically targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. The approval is based on positive results from the HERCULES phase 3 study, which demonstrated a significant delay in disability progression. The safety profile shows common adverse events, including COVID-19 and liver enzyme elevations, necessitating careful monitoring.
Read more →SNYDoH and Sanofi Partner to Advance Vaccine Innovation
The Department of Health – Abu Dhabi and Sanofi have signed a Memorandum of Understanding to advance vaccine innovation. Their collaboration will focus on developing a Vaccine Innovation Centre in Abu Dhabi, enhancing capabilities in AI-enabled vaccine discovery, mRNA research, and manufacturing. This initiative aims to strengthen global health security and support local scientific talent.
Read more →SNYPress Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi has appointed Paulo Fontoura as the new Global Head of R&D, effective September 1, 2026. Fontoura, who has over 25 years of experience in various therapeutic areas, will lead Sanofi's innovation engine and report directly to CEO Belén Garijo. He succeeds Dr. Houman Ashrafian, who is leaving for another opportunity.
Read more →SNYPress Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi's Sarclisa subcutaneous formulation has been approved in Japan for multiple myeloma treatment. This approval is based on the IRAKLIA phase 3 study, which showed non-inferior efficacy compared to the intravenous formulation. The new formulation aims to ease treatment burdens and improve patient convenience. Sarclisa SC is now available in combination with several standard-of-care regimens.
Read more →SNYCommuniqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la santé
Sanofi and HEC Paris have announced the launch of the 'Sanofi MBA Life Sciences Scholarship', aimed at supporting 10 MBA students annually. This initiative seeks to foster a new generation of leaders equipped to navigate the evolving healthcare landscape. The scholarships will cover 75% of tuition for candidates with scientific or medical backgrounds, promoting expertise in management and strategy.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – May 2026
Sanofi has released information regarding the total number of voting rights and shares as of May 2026. This announcement complies with French commercial regulations and is intended for shareholders and investors. Details about the registered capital and the company's registration are also provided, along with a link to further information on Sanofi's website.
Read more →SNYSanofi launches 2026 global employee stock purchase plan Paris
Sanofi has announced the launch of its global employee stock purchase plan, Action 2026, starting June 9, 2026. This 12th edition of the program aims to engage around 75,000 employees across 52 countries. In 2025, nearly half of the workforce participated in the plan, demonstrating their confidence in Sanofi's transformation. The stock will be offered at a 20% discount with an option for employees to receive matching shares, further encouraging investment in the company's future.
Read more →SNYSanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris
Sanofi's investigational drug, venglustat, has received priority review status from the FDA for the treatment of type 3 Gaucher disease, a rare condition with significant neurological impact. If approved by the target date of November 25, 2026, it would be the first therapy specifically addressing the neurological symptoms linked with the disease. Results from the LEAP2MONO phase 3 study indicated that venglustat met its primary endpoints, signaling promise for improved patient outcomes. The drug is also under review in the EU and aims for further global filings in 2026.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - April 2026
Sanofi provided an update on its total number of voting rights and shares as of April 30, 2026. The registered share capital amounts to €2,424,365,088. The total number of issued shares stands at 1,212,212,936, with real voting rights reported at 1,329,027,146. This information is in compliance with the French Commercial Code and relevant financial regulations.
Read more →SNYATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralprin alfa
The ElevAATe phase 2 study presented at ATS 2026 highlighted the superiority of efdoralprin alfa compared to standard therapy for AATD-related emphysema. Results showed significant increases in functional alpha-1 antitrypsin (fAAT) levels and met all primary and key secondary endpoints. Efdoralprin alfa, which can be administered every three weeks, maintained normal fAAT levels consistently better than standard treatments. The study demonstrates an important advancement in addressing the untreated challenges of AATD, with further evaluations ongoing.
Read more →SNYAnnual General Meeting of
Sanofi held its Annual General Meeting on April 29, 2026, where Belén Garijo was appointed as the new Chief Executive Officer, effective May 1, 2026. The meeting saw all proposed resolutions approved, including the endorsement of Garijo's appointment, which is viewed positively due to her extensive background in healthcare management. Additionally, shareholders approved a dividend of 4.12 per share and welcomed Christel Heydemann as an independent board member. The overall composition of the Board reflects a commitment to diversity and governance.
Read more →SNYSanofi successfully prices 2.3 billion of bond issue Paris
Sanofi has successfully priced a bond issuance totaling 2.3 billion euros across three tranches, under its Euro Medium Term Note program. The funds will be utilized for general corporate purposes, reflecting the company's financial strategy to support its operations. The transaction was facilitated by major global coordinators and joint lead managers, indicating robust participation from the investment community.
Read more →SNYESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerab
Sanofi's Nuvaxovid COVID-19 vaccine was found to have significantly lower systemic reactogenicity compared to Moderna's mNEXSPIKE in a head-to-head study presented at the ESCMID Global Congress. The COMPARE study, involving 1,000 adults, demonstrated that Nuvaxovid had fewer and less severe side effects, which could enhance public willingness to get vaccinated as concerns over side effects remain a significant barrier. With implications for improving vaccination rates, Nuvaxovid's performance supports its role in ongoing public health strategies.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - March 2026
Sanofi has released information regarding the total number of voting rights and shares as of March 31, 2026. The company reports a total of 1,212,182,886 issued shares, with 1,332,007,927 real voting rights excluding treasury shares. Additionally, the theoretical number of voting rights including treasury shares is noted to be 1,346,265,685. This information fulfills regulatory requirements as outlined in the French Commercial Code and is also accessible on the Sanofi investor website.
Read more →SNYSanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents
Sanofi announced a Combined General Meeting scheduled for April 29, 2026, at the Palais des Congrès in Paris. Shareholders are invited to participate, and preparatory documents for the meeting will be made available in accordance with legal provisions. The notice of the meeting has been published, providing details on the agenda and voting procedure. Registered shareholders will receive information directly, while bearer shareholders must contact their financial intermediaries.
Read more →SNYSanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-se
Sanofi's lunsekimig has successfully met its primary and key secondary endpoints in phase 2 studies for asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The drug, a bispecific Nanobody, showed a significant reduction in exacerbations and improvements in lung function while maintaining a favorable safety profile. The phase 2b AIRCULES study and phase 2a DUET study provided promising outcomes, supporting lunsekimig's potential in treating respiratory diseases. However, results were mixed in the exploratory VELVET study for atopic dermatitis, where it did not meet its primary endpoint but showed improvements in key secondary measures.
Read more →SNYPress Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Sanofi presented positive results from three phase 3 studies of amlitelimab for moderate-to-severe atopic dermatitis at the AAD Annual Meeting. The studies demonstrated significant improvements in skin clearance and disease severity compared to placebo, with amlitelimab being well-tolerated. The data supports its potential as a treatment option, addressing unmet needs in this patient population.
Read more →SNYPress release: Availability of the Q1 2026 aide-mémoire
Sanofi has announced the availability of its Q1 2026 aide-mémoire, which will assist investors in financial modeling. The document includes details on non-comparable items, foreign currency impacts, and share count. The official Q1 2026 results will be published on April 23, 2026.
Read more →SNYSanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing ov
Sanofi and Regeneron received approval from Japan's Ministry of Health for Dupixent (dupilumab) as the first targeted treatment for adults with moderate-to-severe bullous pemphigoid. The decision was based on results from the LIBERTY-BP-ADEPT phase 2/3 study, which demonstrated that patients on Dupixent experienced significantly higher rates of sustained disease remission compared to those on placebo. The drug is already approved for multiple conditions in Japan, and more than 1.4 million patients are currently receiving Dupixent globally. However, the treatment is associated with a notable rate of adverse events, including conjunctivitis.
Read more →SNYSanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris
Sanofi's investigational drug, venglustat, has earned Breakthrough Therapy designation from the FDA for treating neurological manifestations of type 3 Gaucher disease (GD3). The designation follows promising results from the LEAP2MONO phase 3 study, which demonstrated significant improvements in neurological symptoms compared to existing enzyme replacement therapy. Venglustat is designed to cross the blood-brain barrier and address unmet medical needs in patients with GD3. Sanofi plans to pursue global regulatory filings for the drug during 2026.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - February 2026
Sanofi has released information regarding the total number of voting rights and shares as of February 28, 2026. The registered share capital amounts to €2,424,365,088, with a total of 1,219,502,262 issued shares. The number of real voting rights, excluding treasury shares, is reported as 1,337,158,714, while the theoretical number of voting rights, including treasury shares, stands at 1,353,591,491. This disclosure is made in accordance with French commercial regulations and is available on Sanofi's investor website.
Read more →SNYSanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug designatio
Sanofi's rilzabrutinib has been granted orphan drug designation in Japan for treating IgG4-related disease (IgG4-RD). This designation is based on positive outcomes from a Phase 2 study, indicating reduced disease flares and a favorable safety profile. Rilzabrutinib is currently under evaluation in various rare immune-mediated conditions and has previously gained approvals in other regions for immune thrombocytopenia. However, some reported adverse events could impact patient acceptance and its future market success.
Read more →SNYSanofi Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map
The article discusses a detailed report on Sanofi's digital transformation strategy for 2025. It outlines the company's tech activities, including various innovation programs, partnerships, and technology initiatives. Sanofi is focusing on enhancing its R&D efforts, aiming to advance combination drugs and biologics for precision medicine. The report emphasizes the significance of these strategies in strengthening Sanofi's position in the pharmaceutical and healthcare sectors.
Read more →SNYSanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonst
Sanofi and Regeneron announced FDA approval for Dupixent (dupilumab) as the first treatment specifically for allergic fungal rhinosinusitis (AFRS) in patients aged 6 and older. The approval follows the LIBERTY-AFRS-AIMS phase 3 study, which showed significant improvements in sinus opacification and symptoms compared to placebo. Dupixent is noted to reduce requirements for additional surgery or systemic corticosteroids, addressing a high unmet medical need in managing AFRS. The approval marks Dupixent's ninth indication, reinforcing its role as a valuable treatment for chronic inflammatory diseases.
Read more →SNYSanofi announces leadership evolution in Specialty Care Business Unit Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has...
Sanofi has appointed Manuela Buxo as the new Head of Specialty Care, effective March 1, 2026, succeeding Brian Foard. Buxo, who currently leads the Global Immunology Alliance Franchise, has over 20 years of experience in healthcare and has been instrumental in the growth of Dupixent. The transition aims to ensure continuity and momentum for Sanofi's Specialty Care initiatives.
Read more →SNYBeyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV hospi
A study published in The Lancet Infectious Diseases highlights the benefits of Beyfortus (nirsevimab) for infants beyond their first RSV season. Conducted in Galicia, Spain, the NIRSE-GAL study found an 85.9% reduction in RSV-related hospitalizations during the first season and a 55.3% reduction in the second season for infants immunized during their first RSV season. The study results emphasize the importance of universal RSV immunization strategies and suggest lasting health benefits for infants. The findings will be presented at the upcoming RSVVW '26 conference in Rome, Italy.
Read more →SNYBel n Garijo to become Chief Executive Officer of Sanofi Paris
Sanofi has appointed Belén Garijo as its new Chief Executive Officer, effective after the Annual General Meeting on April 29, 2026. The decision follows the Board's decision to not renew Paul Hudson's mandate, thanking him for his contributions during his six-year tenure. Garijo, the first woman to lead a DAX40 company, has extensive experience, including 15 years at Sanofi in various leadership roles. She is expected to enhance the company's strategy and governance as it prepares for future growth.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – January 2026
Sanofi has released its total number of voting rights and shares as of January 31, 2026, as required by French regulations. The total issued shares amount to 1,219,502,262, with real voting rights at 1,341,656,083 and theoretical voting rights at 1,353,618,860, including treasury shares. This information is part of regulatory compliance under French law and is accessible on their official website.
Read more →SNYSanofi completes the acquisition of Dynavax Paris
Sanofi has completed its acquisition of Dynavax Technologies, which includes the adult hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate currently in phase 1/2 studies. This acquisition is anticipated to enhance Sanofi's position in the adult immunization market by leveraging Dynavax's product offerings and Sanofi's global commercial reach. The acquisition followed a tender offer for all outstanding Dynavax shares, which has now resulted in Dynavax becoming a wholly owned subsidiary of Sanofi and its stock ceasing trading on NASDAQ. Despite the positive outlook, there are risks associated with integration and potential market challenges.
Read more →SNYSanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi for w
Sanofi's rilzabrutinib, an oral Bruton's tyrosine kinase inhibitor, has been designated as a breakthrough therapy by the FDA for the treatment of warm autoimmune hemolytic anemia (wAIHA). Additionally, the drug received orphan designation in Japan for the same condition. These designations are based on clinical trials indicating rilzabrutinib's potential to significantly improve treatment outcomes for patients suffering from this rare autoimmune disorder. Currently, no approved therapies specifically target the underlying cause of wAIHA, highlighting the importance of this development.
Read more →SNYSanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidence
Sanofi's Rezurock has been recommended for conditional marketing authorization in the EU by the CHMP for treating chronic graft-versus-host disease in adults and children over 12 years. Following a prior negative opinion, this positive recommendation is based on safety and efficacy results from multiple studies, including the ROCKstar phase 2 study. The final decision from the European Commission is awaited, which could expand treatment options for patients suffering from this challenging condition.
Read more →SNYSanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with eff
Sanofi's amlitelimab shows potential in treating moderate-to-severe atopic dermatitis as confirmed in the SHORE and COAST 2 phase 3 studies. Results indicate that the drug met all primary endpoints and displayed a favorable safety profile. Amlitelimab is being developed to normalize the immune system without T-cell depletion, and plans for global regulatory submissions are on track for H2 2026. However, some secondary endpoints in the COAST 2 study did not meet statistical significance and potential serious adverse events were recorded.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - December 2025
Sanofi has provided an update on the total number of voting rights and shares as of December 31, 2025. The company, a French soci t e9 anonyme, reported a total of 1,219,502,152 issued shares and 1,341,770,035 real voting rights excluding treasury shares. Additionally, the theoretical number of voting rights, which includes treasury shares, stands at 1,353,630,675. This information complies with the French Commercial Code and regulatory requirements of the French stock market authority.
Read more →SNYSanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patients
Sanofi has received European Commission approval for Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients with stage 2 T1D. This drug is a groundbreaking disease-modifying therapy, marking a significant advancement in T1D treatment. The evidence supporting the approval comes from the TN-10 phase 2 study, which demonstrated a median delay of two years in T1D onset for those treated with Teizeild compared to placebo. The therapy is already approved in several regions outside the EU, including the US and UK.
Read more →SNYSanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in c
Sanofi's Tzield has been accepted for priority review by the FDA to expand its indications to young children with stage 2 type 1 diabetes. This supplemental biologic license application aims to allow Tzield to be administered to patients as young as one year old, potentially delaying the onset of stage 3 T1D. The positive interim data from the PETITE-T1D phase 4 study supports this expansion. If approved, Tzield will be the first disease-modifying therapy for this indication, marking a significant advancement in treatment options for young children.
Read more →SNYSanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris
Sanofi has announced its acquisition of Dynavax Technologies, aimed at enhancing its adult immunization offerings. The acquisition includes Dynavax’s marketed adult hepatitis B vaccine, HEPLISAV-B, and its phase 1/2 shingles vaccine candidate. This strategic move is expected to strengthen Sanofi's presence in the vaccine market and capitalize on the urgent public health need for adult vaccinations. The transaction is valued at approximately $2.2 billion and is anticipated to complete in the first quarter of 2026, subject to customary closing conditions.
Read more →SNYSanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris
Sanofi announced that the FDA has issued a complete response letter for its new drug application of tolebrutinib, intended for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS). The company indicated they are disappointed by this decision, suggesting it reflects a significant shift in the FDA's feedback. Sanofi noted their continued commitment to collaborate with the FDA and contribute to addressing the unmet medical needs of MS patients. In addition, the company has submitted an expanded access protocol to provide further access to the treatment.
Read more →SNYSanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP Appro
Sanofi's Wayrilz has been granted EU approval as the first BTK inhibitor for treating immune thrombocytopenia (ITP) in adult patients with refractory conditions. The approval follows a favorable opinion from the EMA and is based on positive results from the LUNA 3 phase 3 study, which demonstrated beneficial effects on platelet counts and other ITP symptoms. With already existing approvals in the US and UAE, Wayrilz is currently under review in other countries, further emphasizing its significance in treating rare diseases.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - November 2025
Sanofi released information regarding the total number of its voting rights and shares as of November 30, 2025. The company has a registered share capital of €2,438,854,192 and reported a total of 1,227,469,992 issued shares. The number of real voting rights, excluding treasury shares, stands at 1,345,585,094, while the theoretical number of voting rights, including treasury shares, is 1,361,665,420. This disclosure complies with French commercial regulations.
Read more →SNYSanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump's four requests, establishing a framework for lower prices for pa
Sanofi has reached an agreement with the US government to reduce medicine costs while enhancing innovation in biopharmaceuticals. The agreement ensures that state Medicaid programs can access certain Sanofi medicines at prices comparable to other high-income countries, resulting in significant savings for consumers. This partnership not only aims to make medications more affordable but also emphasizes the importance of US leadership in scientific development. The deal includes a three-year exemption from tariffs on imported products.
Read more →SNYSanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi's commitment to developing treatments for ra
Sanofi's efdoralprin alfa has received orphan designation from the European Medicines Agency for the treatment of alpha-1 antitrypsin deficiency-related emphysema. This investigational recombinant protein has shown superiority in clinical trials compared to standard therapies. The FDA had earlier awarded it fast track and orphan drug designations, marking robust regulatory interest. Sanofi aims to present further data at a medical meeting and discuss next steps with global regulatory authorities.
Read more →SNYSanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory
Sanofi has updated the status of its regulatory submission for tolebrutinib, a treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The company anticipates that the review process will extend past the original target action date of December 28, 2025, and expects further guidance from the FDA by the end of Q1 2026. In response to the FDA's request for expanded access, Sanofi has submitted a protocol aimed at allowing eligible patients access to tolebrutinib. The investigational therapy aims to address significant unmet needs in MS by targeting neuroinflammation.
Read more →SNYSanofi completes acquisition of Vicebio Paris
Sanofi has announced the successful completion of its acquisition of Vicebio Ltd, which brings a promising early-stage vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). This acquisition bolsters Sanofi's capabilities in vaccine design and development, particularly by integrating Vicebio's 'Molecular Clamp' technology. The addition of a non-mRNA vaccine to Sanofi's pipeline enhances therapeutic options available to healthcare providers and patients.
Read more →SNYSanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced
The European Commission has approved Dupixent (dupilumab) as the first targeted treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in over a decade. This approval allows eligible patients aged 12 and above, who have not responded adequately to antihistamines, to use Dupixent as a first-line option. The decision is supported by significant reductions in urticaria activity and improvement in patients' symptoms in phase 3 clinical trials. Dupixent is also noted for its established safety profile across various indications.
Read more →SNYBeyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying...
Beyfortus (nirsevimab) has been approved in Malaysia for the prevention of respiratory syncytial virus (RSV) in infants. The drug has shown an 82.7% reduction in RSV hospitalizations in clinical trials and is designed to protect all infants, regardless of their health status. Its availability marks a significant advancement in public health efforts to combat RSV, which poses a substantial risk to infants.
Read more →SNYACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 dat
Sanofi and Regeneron's Dupixent has shown positive results in a pivotal phase 3 study targeting allergic fungal rhinosinusitis (AFRS). The LIBERTY-AFRS-AIMS trial demonstrated significant reductions in disease symptoms, leading to the FDA's acceptance of a supplemental biologics license application for priority review. Dupixent could become the first approved treatment for AFRS if granted FDA approval. This advancement highlights the potential of Dupixent to significantly improve the quality of life for patients suffering from this chronic condition.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – October 2025
Sanofi has released its official report on the total number of voting rights and shares as of October 31, 2025. The company, registered in Paris, shows a total of 1,227,469,992 issued shares with real voting rights amounting to 1,348,747,993. Additionally, the theoretical number of voting rights, including treasury shares, stands at 1,361,720,228. This information is in accordance with French commercial regulations and is accessible on Sanofi's investor website.
Read more →SNYSanofi successfully prices USD 3 billion of bond issue Paris, France
Sanofi has successfully priced a bond issue totaling USD 3 billion, structured across five tranches. The proceeds from this offering are intended for general corporate purposes, further strengthening the company's financial position. The transaction involved several prominent financial institutions, reflecting a positive outlook on Sanofi's prospects in the biopharma sector.
Read more →SNYCondensed half-year consolidated financial statements B.22. Information related to Opella, presented within assets held for sale and discontinued operations On April 30 2025, the Opella transaction was closed (see Note B
Sanofi has released its condensed half-year consolidated financial statements for 2025, revealing various key figures on assets, liabilities, and income. The company incurred a net income of 5,837 million compared to 2,263 million in the previous year. Notably, the financial statements reflect significant changes in current assets, including a substantial decrease in assets held for sale. The documents also provide insights into equity attributable to Sanofi and the impact of discontinued operations, such as the Opella transaction closure.
Read more →SNYSanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
Sanofi has announced an extension of its partnership with Medidata to improve clinical research processes. The collaboration will utilize Medidata's AI-embedded solutions aimed at unifying clinical trial workflows and reducing costs. This partnership builds on a decade of cooperation and aims to expedite the development and delivery of new therapies. Both companies are committed to enhancing patient care and health outcomes globally.
Read more →SNYSanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a sta
Sanofi's investigational treatment efdoralprin alfa achieved positive results in the ElevAATe phase 2 study for alpha-1 antitrypsin deficiency emphysema. The study demonstrated that efdoralprin alfa met all primary and key secondary endpoints, showing a statistically significant increase in functional AAT levels compared to standard therapy. The treatment is well tolerated, with a similar safety profile to existing plasma-derived therapies. Sanofi plans to share the findings at an upcoming medical meeting and engage regulatory authorities for future steps.
Read more →SNYSanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris
Sanofi has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion regarding the marketing authorization application for Rezurock (belumosudil) to treat chronic graft-versus-host disease (cGVHD). Despite the disappointing news, Sanofi plans to request a re-examination of the decision, emphasizing their confidence in the clinical evidence supporting Rezurock's efficacy and safety. The company is focused on providing this treatment to patients in the EU who are in need, building on its existing approvals in multiple countries.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - September 2025
Sanofi has released official information about the total number of voting rights and shares as of September 30, 2025. The company reported a total of approximately 1.23 billion issued shares, with 1.35 billion real voting rights, and a theoretical number of 1.36 billion voting rights including treasury shares. This data ensures compliance with French commercial regulations and is available on the Sanofi investor relations website.
Read more →SNYAlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMe
The ALPHAMEDIX-02 phase 2 study results show that AlphaMedix (212Pb-DOTAMTATE) achieved all primary efficacy endpoints, indicating significant therapeutic benefits for patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. The therapy has demonstrated promising overall response rates and prolonged clinical benefits, with a manageable safety profile. The study included both PRRT-naïve and PRRT-exposed cohorts, and full results will be presented at the upcoming ESMO Congress. In recognition of its potential, AlphaMedix was granted Breakthrough Therapy Designation by the FDA.
Read more →SNYSanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all...
Sanofi US has expanded its Insulins Valyou Savings Program, allowing all patients in the US to access a 30-day supply of any Sanofi insulin for $35. This initiative aims to improve affordability and accessibility for individuals managing diabetes, regardless of their insurance status. The program will be available starting January 1, 2026.
Read more →SNYSanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expressi
Sanofi's gene therapy SAR446268 has received fast track designation from the FDA for treating non-congenital myotonic dystrophy type 1. This one-time AAV gene therapy aims to silence DMPK expression, potentially alleviating symptoms such as muscle weakness and myotonia. SAR446268 is currently undergoing a phase 1-2 clinical trial, with the first patient expected to enroll in late 2025. There are no currently approved therapies for this rare genetic disorder, highlighting the significance of this development.
Read more →SNYSanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significa
Sanofi and Regeneron's Dupixent has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and above. The recommendation is based on data from phase 3 studies indicating that Dupixent significantly reduces itch and hives. While the safety profile aligns with existing indications, some adverse events were observed. A final regulatory decision is anticipated soon.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - August 2025
Sanofi has released information regarding the total number of its voting rights and shares as of August 31, 2025. The company has a registered share capital of €2,454,937,946 and issued a total of 1,227,469,992 shares. The real voting rights, excluding treasury shares, amount to 1,352,853,696, while the theoretical number of voting rights including treasury shares is reported as 1,361,794,887. This information is compliant with the French Commercial Code and is available on Sanofi's official website.
Read more →SNYMandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® Sanofi is partnering with celebrity moms who chose to immunize their babies with BEYFORTUS® (nirsevimab-alip) to help educate families about the...
Sanofi has partnered with celebrity moms, including Mandy Moore, to promote BEYFORTUS, a monoclonal antibody designed to prevent RSV lung infections in infants. This initiative aims to educate families on the importance of RSV protection, particularly as RSV is the leading cause of hospitalization in babies under one year. BEYFORTUS is recommended for all infants, regardless of health status, and has shown effectiveness in clinical studies.
Read more →SNYTzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield's ability to delay the onset
Tzield (teplizumab) has received approval from the Chinese National Medical Products Administration as the first disease-modifying therapy for stage 2 type 1 diabetes in both adults and pediatric patients. This approval follows the promising results from the TN-10 phase 2 study, which showed that Tzield significantly delayed the onset of stage 3 T1D compared to placebo. The therapy promises to preserve beta-cell function and reduce the treatment burden for patients. This development aligns with recent Chinese guidelines emphasizing the importance of protecting beta-cell functionality in type 1 diabetes management.
Read more →SNY▼ -9.1%on this news
Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstr
Sanofi reported positive results from the COAST 1 phase 3 study of amlitelimab, a monoclonal antibody for moderate-to-severe atopic dermatitis. The study demonstrated that amlitelimab met all primary and secondary endpoints, showing significant skin clearance and improved disease severity compared to placebo. Amlitelimab was well-tolerated with no new safety concerns, supporting its potential for use in patients with diverse treatment histories. The results will form the basis for potential future regulatory submissions.
Read more →SNYSanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 pha
Sanofi's Wayrilz (rilzabrutinib) has been approved by the US FDA as the first Bruton's tyrosine kinase (BTK) inhibitor for adults suffering from persistent or chronic immune thrombocytopenia (ITP) who have not adequately responded to previous treatments. This approval stems from the results of the LUNA 3 phase 3 study, which demonstrated significant improvements in platelet counts and quality of life measures. Sanofi's unique multi-immune modulation approach with Wayrilz aims to tackle the underlying causes of ITP, offering new hope for affected patients. Wayrilz has also received approvals in the UAE and is under review in the EU and China.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi has published information regarding the total number of voting rights and shares as of July 31, 2025. The report, required by French commercial regulations, details the number of issued shares as well as the actual and theoretical voting rights, which include treasury shares. With a registered capital of approximately €2.45 billion, the company's data indicates a total of over 1.35 billion real voting rights. This information is accessible on Sanofi's official website under 'Regulated Information in France.'
Read more →SNYBeyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus...
The Health Sciences Authority in Singapore has approved Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) in infants. This approval allows for protection from birth and is aimed at infants up to 24 months old who are vulnerable to severe RSV disease. Clinical trials demonstrated a significant reduction in RSV hospitalizations, with a favorable safety profile. The approval is seen as a critical step in improving public health for infants in Singapore.
Read more →SNYSanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR
Sanofi's rilzabrutinib has been granted orphan designation by the European Medicines Agency for the treatment of IgG4-related disease. The approval follows positive results from a Phase 2 study presented at the EULAR 2025 Congress, showing reduced disease flare and maintenance of safety profiles. Rilzabrutinib also holds orphan designations for other conditions, including immune thrombocytopenia, and is under regulatory review in multiple regions. Its effective use for IgG4-RD may help address the urgent healthcare challenges posed by this rare disease.
Read more →SNYSanofi completes the acquisition of Vigil Neuroscience, Inc. Paris
Sanofi has completed the acquisition of Vigil Neuroscience, Inc., which enhances its neurology pipeline with the addition of VG-3927, an oral TREM2 agonist destined for phase 2 studies in Alzheimer's disease. The acquisition also includes Vigil's preclinical pipeline, further advancing Sanofi's research efforts in neurodegenerative diseases. Notably, the acquisition will not impact Sanofi's financial guidance for 2025, allowing the company to maintain its strategic focus and innovative capabilities in biopharmaceuticals.
Read more →SNY▼ -7.3%on this news
Half-year management report 4. Responsibility statement of the certifying officer half-year financial report "I hereby certify that, to the best of my knowledge, the condensed half-year consolidated financial statements
Sanofi reported a strong performance in the first half of 2025, with net sales increasing by 8.3% compared to the same period in 2024. Key highlights include the successful approval of Dupixent for bullous pemphigoid and several important acquisitions that expand its research and development pipeline. The company achieved a significant net income rise, benefiting from its strategic initiatives and focus on innovation. However, the integration of acquired companies and regulatory challenges present risks for future operations.
Read more →SNYSanofi s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatme
Sanofi's Sarclisa has received approval from the European Commission for the treatment of transplant-eligible adults with newly diagnosed multiple myeloma. This approval follows a positive opinion from the EMA based on results from the phase 3 GMMG-HD7 study, which illustrated better outcomes when Sarclisa is used with VRd compared to VRd alone. The study demonstrated significant improvements in minimal residual disease negativity and progression-free survival. Sanofi aims to extend Sarclisa's reach to more patients in the EU, reinforcing its commitment to oncology.
Read more →SNYBEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints,...
The largest US real-world study of BEYFORTUS (nirsevimab-alip) demonstrated significant efficacy in preventing RSV disease in infants, showing an 87% reduction in cases and a 98% reduction in hospitalizations. Conducted during the 2023-2024 RSV season, the study supports the use of BEYFORTUS for all infants, regardless of health status. The findings have been published in the journal PEDIATRICS.
Read more →SNYSanofi completes acquisition of Blueprint Medicines Paris
Sanofi has successfully completed its acquisition of Blueprint Medicines Corporation, bolstering its offerings in the field of immunology. This acquisition includes the approved treatment Ayvakit for systemic mastocytosis, alongside promising investigational drugs like elenestinib and BLU-808. The merger enhances Sanofi's capabilities, particularly among allergists and dermatologists, and is anticipated to support the growth of its immunology pipeline. The acquisition was fully financed and is expected to be accretive to Sanofi's gross margin and business operating income post-2026.
Read more →SNYSanofi s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit two k
Sanofi's SAR446597 has received fast track designation from the FDA for the treatment of geographic atrophy caused by age-related macular degeneration. This one-time intravitreal gene therapy incorporates a dual-targeting approach to inhibit key components of complement pathways, which may alleviate some treatment burdens associated with frequent injections. The company plans to initiate a phase 1/2 clinical study to assess the safety and efficacy of SAR446597. This development holds promise for a significant number of patients suffering from this serious condition, which impacts millions globally.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - June 2025
Sanofi has provided information regarding the total number of voting rights and shares as of June 30, 2025. The company has a registered share capital of €2,452,461,656 and issued 1,227,756,274 shares. The report indicates that there are 1,351,296,496 real voting rights and 1,361,952,562 theoretical voting rights. This data complies with French regulatory requirements and is available on Sanofi's official website.
Read more →SNYSanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits...
Sanofi has launched its Healthy Futures Solution Fund, awarding over $1 million in grants to local nonprofits in Massachusetts. This initiative aims to enhance community-led health solutions and improve access to care in historically underserved areas. The funding will support various programs addressing social determinants of health, with a focus on measurable impact over the next year.
Read more →SNYRiliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of
Sanofi's riliprubart has been granted orphan drug designation by the FDA for the treatment of antibody-mediated rejection in solid organ transplantation. This designation highlights the drug's potential to address a significant challenge in transplant medicine where no FDA-approved therapies currently exist. An ongoing phase 2 study is investigating riliprubart's effectiveness in kidney transplant recipients. Sanofi aims to leverage its expertise in immunology to provide new treatment options for patients at risk of rejection.
Read more →SNYSanofi successfully prices 1.5 billion bond issue Paris
Sanofi has successfully priced a bond offering worth 1.5 billion euros, structured in two tranches, which will be issued under its Euro Medium Term Note Programme. The proceeds from this bond issuance are intended to support the company’s general corporate purposes. The transaction has been coordinated by Citigroup and RBC Capital Markets, indicating confidence in Sanofi's financial strategies.
Read more →SNYEAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory stud
Sanofi and Regeneron presented positive results from the EVEREST phase 4 study, which showed that Dupixent outperformed Xolair in treating severe chronic rhinosinusitis with nasal polyps in adults with coexisting asthma. This study is the first head-to-head comparison of two biologic medications for this condition. The findings suggest that Dupixent not only improved nasal polyp scores but also enhanced asthma-related outcomes, supporting its role as a primary treatment option. The safety profiles of the two medications were reported to be generally similar, highlighting Dupixent's potential for broader use in this patient population.
Read more →SNYSanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris
Sanofi is ramping up the global shipment of its RSV prevention drug, Beyfortus, in anticipation of the 2025-2026 season. This proactive measure is designed to ensure healthcare providers are prepared well in advance of the RSV season, which typically runs from November to March. With production capacity tripled and the number of manufacturing sites doubled since Beyfortus' launch, sufficient supply is already in place to meet growing demand. Notably, this year's EU label extension allows for a six-month duration of protection, enhancing its effectiveness across diverse infant populations.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - May 2025
Sanofi has released information regarding the total number of voting rights and shares as of May 31, 2025. The company reported having 1,227,755,892 issued shares and 1,351,729,644 real voting rights, which do not include treasury shares. Additionally, the theoretical number of voting rights, which includes treasury shares, is 1,361,952,180. This information is required to comply with French commercial regulations and is accessible on Sanofi's investor relations website.
Read more →SNYRilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseases Under regulatory review in the US, the EU, and China in immu
The FDA has granted orphan drug designation to rilzabrutinib for sickle cell disease, marking the fourth such designation for the drug in treating rare diseases. Rilzabrutinib is an advanced oral BTK inhibitor aimed at reducing vaso-occlusive crises. Its efficacy is still under regulatory review, with promising preclinical data indicating a reduction in blockage of blood vessels and inflammation in models of sickle cell disease. Sanofi continues to seek novel treatments to meet the unmet medical needs associated with this condition.
Read more →SNYSanofi Exercises License Extension Option to Nurix’s STAT6 Program
Sanofi has exercised its option to extend the license for Nurix's STAT6 program, including the candidate NX-3911, an oral STAT6 degrader. This move comes under their ongoing collaboration established in 2019, which has already seen Nurix receive a total of $127 million. In addition to the recent $15 million fee, Nurix stands to gain up to $465 million in milestones related to the development and commercialization of the STAT6 program. The STAT6 degrader has demonstrated significant anti-inflammatory effects in preclinical models, offering promising prospects for treating conditions like asthma and atopic dermatitis.
Read more →SNYSanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent
Sanofi has announced its acquisition of Blueprint Medicines for approximately $9.1 billion, which includes the rare disease drug Ayvakit and early-stage immunology therapies. This strategic move aims to expand Sanofi's presence in the field of rare immunological diseases. The deal will enhance Sanofi's existing immunology pipeline and is expected to grow its market presence significantly. Though the acquisition is largely viewed as favorable, it is subject to customary closing conditions and regulatory approvals.
Read more →SNYSanofi completes acquisition of DR-0201 Paris
Sanofi has completed its acquisition of DR-0201 from Dren Bio, now designated as SAR448501. This bispecific myeloid cell engager is aimed at treating B-cell mediated autoimmune diseases by inducing deep B-cell depletion. Sanofi's acquisition is expected to strengthen its immunology portfolio, particularly in addressing unmet needs in conditions like lupus. The deal involves an upfront payment of $600 million and potential future milestone payments of $1.3 billion.
Read more →SNYSanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer s disease to the neurology pipeline Paris
Sanofi has agreed to acquire Vigil Neuroscience, Inc., integrating their investigational medicine VG-3927 into its neurology pipeline. This oral TREM2 agonist is aimed at treating Alzheimer's disease and represents a strategic move to enhance Sanofi's offerings in neurodegenerative diseases. The transaction is set to close in Q3 2025, pending regulatory approvals and stockholder consent, and will not impact Sanofi's financial guidance for the year. Vigil's experience in TREM2-based therapies complements Sanofi's existing capabilities in neurology, potentially unlocking new treatment avenues for Alzheimer's patients.
Read more →SNYSanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering...
Sanofi has officially opened its new flagship US offices in Morristown, New Jersey, with a $130 million investment. The state-of-the-art facility aims to foster collaboration and innovation among nearly 2,000 employees. Designed with sustainability in mind, the building will achieve LEED Gold Certification and includes various amenities to enhance employee well-being. Additionally, Sanofi is committed to supporting local healthcare initiatives.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - April 2025
Sanofi has published an update concerning its total number of voting rights and shares as of April 30, 2025. The report indicates that the number of issued shares stands at 1,226,230,828, with a real voting rights total of 1,348,348,742 and a theoretical voting rights number of 1,359,092,889. This disclosure complies with regulations set forth by French financial authorities, emphasizing the company's commitment to transparency in corporate governance.
Read more →SNYSanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment includes a significant ...
Sanofi has announced a commitment to invest at least $20 billion in the United States by 2030, focusing on research and development as well as expanding domestic manufacturing capabilities. This investment aims to enhance the health of Americans and contribute to job creation and innovation. The company anticipates that these efforts will ensure the production of key medicines in the US.
Read more →SNYSanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights
Sanofi is generating high physician interest in its asthma pipeline according to new insights from Spherix Global Insights. The report highlights a significant opportunity for innovation due to persistent unmet needs in the treatment of severe asthma. Emerging therapies, including those from Sanofi, are gaining traction with physicians who believe they may surpass existing standards of care. In contrast, GSK's advanced asset, depemokimab, is facing challenges in enthusiasm from prescribers, particularly concerning dosing frequency and patient adherence. As the asthma treatment landscape evolves, the need for effective, differentiated therapies remains critical.
Read more →SNYDupixent approved in Singapore as the first-ever biologic medicine for patients with COPD The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic...
The Health Sciences Authority in Singapore has approved Dupixent (dupilumab) as the first biologic treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). This decision follows successful phase 3 studies showing significant reductions in exacerbations and improvements in lung function. Dupixent is developed by Sanofi and Regeneron, targeting patients with specific eosinophilic characteristics.
Read more →SNYSanofi: Investing in prevention builds Europe’s health and competitiveness
Sanofi has been actively promoting a proactive approach to healthcare at the European Economic Congress, advocating for a shift from reactive treatments to preventive strategies. The discussions emphasized the pivotal role of immunization and sustainable innovation in improving public health outcomes and boosting economic resilience in Europe. Experts highlighted the significant returns on investments in prevention and called for a strengthened focus on digital health and collaboration between industry and academia to ensure future competitiveness. The focus remains on using innovation to enhance lives and not just healthcare outcomes.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - March 2025
Sanofi has published information regarding the total number of voting rights and shares as of March 31, 2025. The company reports a registered share capital of €2,452,461,656 and a total of 1,233,737,221 issued shares. The actual number of voting rights, excluding treasury shares, is noted to be 1,351,370,330, while the theoretical number, including treasury shares, is 1,366,610,643. This information is disclosed in compliance with French commercial law and is accessible through their official website.
Read more →SNYSanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris
Sanofi has finalized the sale of a 50% controlling stake in its consumer healthcare business, Opella, to Clayton, Dubilier & Rice (CD&R), while retaining a 48.2% stake. This transaction is a strategic move for Sanofi, enabling it to focus solely on its biopharmaceutical operations. Opella is expected to grow independently with the support of CD&R, leveraging its renowned expertise in the consumer healthcare market. The company aims to expand its influence globally while continuing to serve consumers with its established health products.
Read more →SNYDupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives
Dupixent has received FDA approval as the first new targeted therapy for chronic spontaneous urticaria (CSU) in over ten years. This decision is based on phase 3 clinical trials showing that Dupixent significantly reduced symptoms, including itch and hives, in patients who did not respond to standard antihistamine treatments. With this approval, Dupixent now offers new hope to over 300,000 CSU patients in the US seeking relief from their debilitating symptoms.
Read more →SNYSanofi s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now t
Sanofi has announced advancements in its respiratory pipeline, particularly highlighting the preliminary phase 2 results for amlitelimab in asthma. Although the primary endpoint was not achieved at the highest dose, the drug exhibited nominally significant reductions in asthma exacerbations at a medium dose. The company plans to initiate new clinical studies for both asthma and chronic obstructive pulmonary disease (COPD), reinforcing its commitment to addressing unmet patient needs in respiratory diseases. Further results, including those from the TIDE-Asthma study, will be presented at upcoming medical meetings.
Read more →SNYChrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement Sanofi, a leader in diabetes care, welcomes author, entrepreneur, and mom Chrissy Teigen as its new celebrity spokesperson for the Screen For Type 1...
Sanofi has appointed Chrissy Teigen as the spokesperson for its Screen For Type 1 movement, which promotes early screening for type 1 diabetes. Teigen's advocacy is inspired by her son's unexpected diagnosis, emphasizing the importance of early detection. The initiative aims to educate families about the benefits of screening, potentially preventing serious health complications.
Read more →SNYTolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people livin
The New England Journal of Medicine published positive results from the HERCULES phase 3 study, which demonstrated that tolebrutinib effectively delays disability progression in individuals with non-relapsing secondary progressive multiple sclerosis (nrSPMS). With no currently approved treatments for this condition, these findings suggest a significant advancement for managing an unmet medical need. The study also showed tolebrutinib's mechanism of action by targeting disability progression independent of relapse activity. However, safety concerns include reported liver enzyme elevations in some participants. Regulatory evaluations for tolebrutinib by the FDA and EU are underway.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - February 2025
Sanofi has released information regarding the total number of voting rights and shares as of February 28, 2025. The report states that the company has a registered share capital of €2,467,152,142 and lists the total number of issued shares as 1,263,132,721. Additionally, it specifies the number of real voting rights at 1,354,221,504 and the theoretical number of voting rights at 1,396,197,561. This information is distributed in accordance with French regulations and is available on the company's website.
Read more →SNYRilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is cu
The US FDA has granted orphan drug designation to rilzabrutinib for two rare autoimmune diseases: warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD), which currently lack approved therapies. This designation aims to facilitate the development of treatments for conditions affecting fewer than 200,000 individuals in the US. Rilzabrutinib is also under review for immune thrombocytopenia (ITP), with its regulatory decision expected by August 2025. Clinical study results indicate promising outcomes for patients treated with rilzabrutinib in both conditions, thus reinforcing its potential as a novel therapeutic option.
Read more →SNYDupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults wi
The Ministry of Health, Labour and Welfare in Japan has approved Dupixent (dupilumab) as the first biologic medicine for chronic obstructive pulmonary disease (COPD) treatment. This approval follows significant phase 3 results showing that Dupixent effectively reduced exacerbations and improved lung function in adults with uncontrolled COPD. This milestone adds to Dupixent's extensive global approvals across various indications, highlighting its role in transforming treatment for chronic diseases driven by type-2 inflammation.
Read more →SNYTolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both tre
Tolebrutinib's regulatory submission for treating non-relapsing secondary progressive multiple sclerosis has been accepted for priority review in the US. The FDA is expected to make a decision by September 28, 2025. This BTK inhibitor aims to address disability accumulation independent of relapse activity, with clinical backing from phase 3 studies. Additionally, submissions are under review in the EU, highlighting its potential significance in multiple sclerosis treatment.
Read more →SNYSanofi to acquire Dren Bio s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune system Acqu
Sanofi has entered into a definitive agreement to acquire Dren Bio's bispecific myeloid cell engager, DR-0201, which targets B-cell depletion for the treatment of autoimmune diseases. The acquisition, valued at $600 million upfront plus potential future payments, is aimed at strengthening Sanofi's immunology pipeline. DR-0201 has shown promising results in early studies, suggesting its potential to reset the adaptive immune system in patients with autoimmune conditions. The transaction is expected to close in Q2 2025, subject to regulatory approvals.
Read more →SNYSanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing ...
Sanofi has announced the immediate adoption of influenza strains selected by the FDA to enhance its vaccine portfolio for the 2025-26 flu season. The company is already producing vaccines to ensure a robust supply, with plans to begin shipping this summer. This initiative comes amid a severe flu season in the US, highlighting the importance of vaccination.
Read more →SNYDupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reduc
Positive pivotal data for Dupixent in treating moderate-to-severe bullous pemphigoid was presented at the 2025 AAD Annual Meeting. The ADEPT study demonstrated that Dupixent significantly outperformed placebo in achieving sustained disease remission over 36 weeks. The investigational biologic targets underlying type 2 inflammation, offering a new therapeutic approach for patients suffering from this debilitating skin disease. The treatment's FDA application for BP is currently under priority review, with a decision expected by June 20, 2025.
Read more →SNYSanofi successfully prices EUR 1.5 billion of bond issue Paris
Sanofi has successfully priced a bond issue totaling EUR 1.5 billion as part of its Euro Medium Term Note Program. The net proceeds from this offering will be allocated for general corporate purposes, which could enhance the company's operational capabilities. This transaction is being coordinated by Deutsche Bank and J.P. Morgan, along with support from ING, Santander CIB, and Unicredit. The notes are not intended for retail investors in the European Economic Area and the UK, which limits their availability.
Read more →SNYECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn s disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in al
Sanofi and Teva Pharmaceuticals presented new data from the RELIEVE UCCD phase 2b study on duvakitug, highlighting its efficacy in moderate-to-severe ulcerative colitis and Crohn's disease. The study showed that a greater proportion of patients receiving duvakitug achieved clinical remission compared to placebo, with variations between the dosages. Safety assessments indicated that duvakitug was well tolerated without significant adverse effects. These findings support the potential of duvakitug as a viable treatment option for patients suffering from inflammatory bowel diseases.
Read more →SNYDupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expect
The FDA has accepted the supplemental biologics license application for Dupixent, which aims to treat adults with bullous pemphigoid. The application is backed by positive clinical data showing that Dupixent led to substantially higher rates of sustained disease remission compared to placebo. If approved, Dupixent would become the first targeted therapy available for this condition in the United States. However, adverse events have been noted in patients taking Dupixent, and the therapy's overall safety and efficacy for this indication are still under evaluation.
Read more →SNYUpdate on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn t demonstrate sufficient efficacy
Sanofi's vaccine candidate for extraintestinal pathogenic E. coli did not show sufficient efficacy to continue the phase 3 E.mbrace study, which has now been discontinued following an independent interim analysis. The trial was aimed at evaluating its potential to prevent invasive E. coli disease, particularly in older adults with a history of urinary tract infections. Despite the setback, no safety concerns were found during the study. The discontinuation has resulted in a significant impairment charge for Sanofi but does not affect overall business income projections.
Read more →SNYExecution of a share buyback agreement for up to 2 billion Paris
Sanofi has announced the execution of a share buyback program for up to 2 billion euros, which will take place between February 7, 2025, and December 31, 2025. This initiative follows a previous tranche of 3 billion euros executed earlier in the month through block trades, primarily with its long-standing shareholder, L'Oréal. The buyback is part of a broader program aiming for a total of 5 billion euros, indicating strong confidence in the company's financial position and future prospects.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - December 2024
Sanofi has released information regarding the total number of its voting rights and shares as of December 31, 2024. The announcement highlights that the company has a registered share capital of €2,526,245,442 and details the total number of issued shares, as well as the number of real and theoretical voting rights. This information complies with the French Commercial Code and the regulations of the French stock market authority. Shareholders and investors can find further details on Sanofi's official website.
Read more →SNYOpella reaches study milestone for Cialis Paris
Opella, a Sanofi subsidiary, has announced that the FDA lifted a clinical hold on their actual use trial (AUT) for Cialis, paving the way for its transition from prescription to over-the-counter status. This milestone positions Cialis as the first PDE-5 inhibitor to achieve such a status, allowing consumers to self-diagnose and treat erectile dysfunction. The AUT will assess real-world usage of Cialis, ensuring appropriate consumer use without healthcare provider intervention. The company expresses optimism about enhancing access to this treatment option for users.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – November 2024
Sanofi has released information concerning its total number of voting rights and shares as of October 31, 2024. The report, compliant with the French Commercial Code and financial regulations, details 1,268,922,721 issued shares and 1,413,173,242 real voting rights. This data is vital for shareholders and available on Sanofi's official website. The report underscores Sanofi's commitment to transparency in its corporate governance.
Read more →SNYSarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive r
Sarclisa has received approval from China's National Medical Products Administration as the first anti-CD38 treatment in combination with standard-of-care VRd for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval is based on positive results from the IMROZ phase 3 study and highlights Sanofi's commitment to patient-centric oncology solutions. The introduction of this treatment option represents a significant advancement in therapeutic choices for these patients. Sanofi also aims to expand Sarclisa's availability further in other regions, such as Japan.
Read more →SNYNew Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints i
The IRAKLIA phase 3 study demonstrated that the subcutaneous formulation of Sarclisa, in combination with pomalidomide and dexamethasone, successfully met its co-primary endpoints for patients with relapsed or refractory multiple myeloma. The study reported comparable efficacy and a favorable safety profile when contrasted with the intravenous formulation. This advancement offers a promising new administration method that may ease treatment delivery for patients. Additional studies regarding the Sarclisa SC formulation are ongoing, with regulatory submissions planned for mid-2025.
Read more →SNYJean-Paul Kress to join Sanofi s Board of Directors Paris
Sanofi has announced the appointment of Jean-Paul Kress as an independent director on its Board of Directors, effective January 1, 2025. Kress replaces Gilles Schnepp, who will step down at the end of 2024. With a robust background in pharmaceutical leadership, particularly in cancer and autoimmune disease treatment, Kress is anticipated to bring valuable insights to Sanofi's strategic direction. His term will be confirmed at the upcoming Ordinary Shareholders Meeting.
Read more →SNYTolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-relapsi
The FDA has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This designation follows positive results from the HERCULES phase 3 study, which demonstrated a 31% delay in disability progression compared to placebo. Despite the promising clinical results, there were concerns regarding liver enzyme elevations observed in some participants. Sanofi is finalizing regulatory submissions for the US and EU and anticipates further studies and results for related conditions.
Read more →SNYAvailability of the profit and loss information of Sanofi excluding Opella Paris, France
Sanofi has made available its profit and loss information, excluding its consumer healthcare segment, Opella, following a planned sale of a controlling stake to CD&R. This update provides a clearer financial picture for investors and includes detailed data on sales and net income. The classification of Opella as discontinued operations aligns with Sanofi's strategy to focus on core biopharma activities. The Q4 2024 results, reflecting this new scope, are set to be published on January 30, 2025.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - October 2024
Sanofi has released information regarding the total number of voting rights and shares as of October 31, 2024, in accordance with French commercial regulations. The company has 1,268,922,721 issued shares, with real voting rights totaling 1,413,229,859, and a theoretical number of voting rights, including treasury shares, amounting to 1,428,560,940. This information is part of the company's regulatory requirements and is accessible on their official website.
Read more →SNYSarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd si
The CHMP has recommended Sarclisa for EU approval to treat newly diagnosed multiple myeloma patients who are not eligible for stem cell transplants. The recommendation is based on the IMROZ phase 3 study, which demonstrated significant improvement in progression-free survival when Sarclisa was combined with VRd. If approved, this treatment could fill a critical gap in the current therapeutic options and set a new standard of care in Europe. Sarclisa is already approved in over 50 countries, further reinforcing its established safety profile.
Read more →SNYDupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixen
Dupixent has been approved by the European Medicines Agency as the first and only treatment for eosinophilic esophagitis in young children aged one to 11 years. This approval is based on promising results from phase 3 clinical studies demonstrating significant efficacy in this age group. Dupixent is already approved for similar indications in the US and Canada, marking a significant milestone for pediatric patients who previously had limited treatment options. The approval aims to enhance the care and wellbeing of children suffering from this chronic and challenging condition.
Read more →SNYDupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-cont
Late-breaking positive phase 3 data for Dupixent, presented at the ACAAI 2024 Annual Scientific Meeting, shows significant reductions in itch and hive activity in patients with chronic spontaneous urticaria (CSU). In a study of 151 patients, Dupixent demonstrated greater efficacy than placebo, with 41% achieving well-controlled disease status after 24 weeks. The safety profile was consistent with previous findings, reinforcing Dupixent's potential in treating CSU.
Read more →SNYSanofi and Orano join forces to develop next-generation radioligand medicines Paris
Sanofi and Orano have formed a partnership to advance the development of next-generation radioligand medicines, specifically targeting rare cancers. This collaboration will leverage Orano's expertise and pipeline in targeted alpha therapies and is backed by an equity investment from Sanofi valued at approximately $300 million. The new entity, operating under Orano Med, will focus on the discovery and clinical development of lead-212 based therapies. The partnership aims to transform treatment standards for patients suffering from difficult-to-treat cancers, contributing to broader innovations in oncology.
Read more →SNYSanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity ...
Sanofi has announced an $18 million investment over 10 years to support Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine in increasing diversity in clinical studies. The funding will be used for hiring clinical research staff and establishing necessary infrastructure. This initiative aims to improve representation in healthcare research and enhance health equity.
Read more →SNYFLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals...
Sanofi has updated the FLUBLOK influenza vaccine label to include new safety data from a study involving over 48,000 pregnant individuals. The findings, published in the American Journal of Obstetrics and Gynecology, indicate that FLUBLOK's safety profile is comparable to standard-dose flu vaccines. This update aims to inform pregnant individuals about the importance of vaccination during flu season.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - September 2024
Sanofi has released information regarding the total number of voting rights and shares as of September 30, 2024. The registered capital of the company stands at €2,537,214,304, with a total of 1,268,914,366 issued shares. The report includes details on real and theoretical voting rights, highlighting 1,413,296,497 real voting rights and a theoretical number of 1,428,630,140 when including treasury shares. This information complies with French regulations and is available on Sanofi's official website.
Read more →SNYNew Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris
Sanofi is set to present new data on its RSV treatment, Beyfortus, at IDWeek 2024 in Los Angeles. The data highlight Beyfortus's real-world effectiveness exceeding 80% against RSV disease and hospitalization in infants. Beyfortus is noted for its favorable safety profile, offering a one-time dose to protect infants, regardless of health status or age. The company has reinforced its manufacturing capabilities to ensure availability for the upcoming RSV season.
Read more →SNYDupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmar
Dupixent has been approved by China's National Medical Products Administration as the first biologic treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This approval is based on successful outcomes from phase 3 studies, which demonstrated that Dupixent significantly reduced COPD exacerbations and improved lung function. The launch of Dupixent addresses a critical need in China, where many COPD patients struggle to manage their condition with existing therapies. Furthermore, this approval adds to Dupixent's established safety and efficacy profile observed in over 30 countries worldwide.
Read more →SNYSanofi: Polens EU-Ratspräsidentschaft - den Weg für eine wettbewerbsfähige Pharmaindustrie ebnen Während sich Polen auf seine EU-Ratspräsidentschaft vorbereitet, muss die Gesundheit angesichts ihrer entscheidenden Rolle für den Wohlstand und die...
As Poland prepares for its EU presidency, health policy will be a key focus, particularly in enhancing the pharmaceutical industry's competitiveness. The proposed new drug legislation aims to strengthen the regulatory framework and ensure timely access to essential medicines. However, there are concerns that this legislation may inadvertently increase regulatory burdens on companies, impacting innovation and patient access.
Read more →SNYSanofi : Présidence polonaise de l'UE - Ouvrir la voie à une industrie pharmaceutique compétitive Alors que la Pologne se prépare pour sa présidence de l'UE , la santé doit être au centre des préoccupations, étant donné son rôle crucial dans la...
La Pologne se prépare à sa présidence de l'UE en mettant l'accent sur la santé, avec une législation pharmaceutique visant à améliorer l'accès aux médicaments et vaccins. Sanofi souligne l'importance de cette réforme pour la compétitivité de l'Europe et la nécessité d'une transformation numérique des soins de santé. Des initiatives de prévention, notamment en matière de vaccination, sont également prioritaires.
Read more →SNYSanofi: Poland's EU Presidency - Paving the Way for a Competitive Pharmaceutical Industry As Poland prepares for its EU Presidency, health needs to be a major focus, given its crucial role in Europe's prosperity and global competitiveness. ...
As Poland prepares for its EU Presidency, health is a priority, focusing on new pharmaceutical legislation to enhance Europe's competitiveness. Sanofi highlights the importance of vaccination and digital health transformation. However, there are concerns about increased regulatory burdens that may hinder drug development. The Presidency aims to address health prevention and mental health initiatives.
Read more →SNYSanofi:la presidencia polaca de la UE allana el camino para una industria farmacéutica competitiva Mientras Polonia se prepara para su presidencia de la UE, la salud debe ser una prioridad, dado su papel crucial en la prosperidad de Europa y la...
As Poland prepares for its EU presidency, health is set to be a key priority, focusing on pharmaceutical legislation to enhance competitiveness in Europe. Sanofi's leadership highlights the importance of vaccination and preventive health initiatives. However, there are concerns that the new legislation may impose additional regulatory burdens that could stifle innovation and access to essential medicines.
Read more →SNYTolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show that tolebru
Tolebrutinib, in the HERCULES phase 3 study, showed a 31% delay in confirmed disability progression for non-relapsing secondary progressive multiple sclerosis. Additionally, nearly 10% of patients experienced disability improvement, highlighting its potential therapeutic benefits. However, the study noted a higher incidence of liver enzyme elevations in patients treated with tolebrutinib, with one serious adverse event leading to a liver transplant. The company intends to discuss these findings with regulatory authorities as part of its ongoing clinical development.
Read more →SNYSanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for...
Sanofi is distributing BEYFORTUS (nirsevimab-alip) in the US to protect infants against RSV disease. The FDA has approved a new manufacturing line to enhance supply ahead of the RSV season. The company aims to ensure that all eligible babies have access to the treatment during their first RSV season, demonstrating a commitment to equitable healthcare.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - August 2024
Sanofi reported its total number of voting rights and shares as of August 31, 2024. The total number of issued shares is 1,268,767,876, with 1,413,467,842 real voting rights, and a theoretical number of 1,428,801,485 voting rights when including treasury shares. This data is mandated by French commercial regulations and is made available on Sanofi's investor relations website.
Read more →SNYDupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoin
Dupixent has demonstrated significant efficacy in a pivotal study (ADEPT) for treating adults with moderate-to-severe bullous pemphigoid, surpassing placebo in achieving sustained disease remission. The drug's success in meeting all primary and secondary endpoints highlights its potential to improve treatment paradigms in this area, especially given the debilitating nature of the disease. The results are expected to support regulatory submissions worldwide, beginning in the U.S. However, a separate phase 3 study on chronic pruritus showed no statistical significance for its primary endpoint.
Read more →SNYTolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study
Sanofi's tolebrutinib has successfully met the primary endpoint in the HERCULES phase 3 study, demonstrating its efficacy in delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This landmark study positions tolebrutinib as a potential first-in-disease treatment option, addressing a significant unmet medical need in this patient population. The positive outcomes will be presented at the upcoming ECTRIMS medical meeting, with further studies ongoing to assess its effects in other forms of multiple sclerosis.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - July 2024
Sanofi has released information regarding the total number of voting rights and shares as of July 31, 2024. The report indicates that the company has a registered share capital of €2,537,214,304. As of the specified date, there are 1,268,607,152 issued shares, alongside 1,413,447,665 real voting rights and a theoretical count of 1,428,781,308 voting rights including treasury shares. This disclosure is in compliance with the French Commercial Code and regulations set by the French stock market authority.
Read more →SNYSarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in combination with
The GMMG-HD7 phase 3 study revealed that Sarclisa (isatuximab), when combined with RVd, significantly prolonged progression-free survival in transplant-eligible patients with newly diagnosed multiple myeloma. This two-part study demonstrates clinically meaningful reductions in disease progression or death compared to traditional RVd treatments. Notably, the combination also resulted in improved rates of minimal residual disease negativity. Future research will further explore long-term outcomes and the potential adoption of this regimen as a new standard of care.
Read more →SNYTABLE OF CONTENTS 2 HALF-YEAR MANAGEMENT REPORT 37 A Significant events of the first half of 2024 37 B Progress on implementation of the Corporate Social Responsibility strategy 40 C Events subsequent to June 30 , 2024 4
In the first half of 2024, Sanofi continued to implement its "Play to Win" strategy with key leadership changes and strategic partnerships. Significant events included the acquisition of Inhibrx and a licensing agreement with Novavax to enhance their vaccine portfolio. The company's financial performance showed a modest increase in net sales but a notable decline in net income. Additionally, they achieved several regulatory approvals for Dupixent, broadening its therapeutic applications for pediatric populations and atopic dermatitis.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – June 2024
Sanofi has published information regarding the total number of voting rights and shares as of June 30, 2024, in compliance with French regulations. The company has a registered capital of €2,537,214,304 and a total of 1,266,362,756 issued shares. The report indicates that there are 1,411,096,877 real voting rights and a theoretical number of 1,426,430,520 voting rights, which includes treasury shares. This information is part of mandatory corporate disclosures under French law and is made available on Sanofi’s official website.
Read more →SNYSanofi ships U.S. influenza vaccines for the 2024/25 season Sanofi today started shipping its first influenza (flu) vaccines across the U.S. in preparation for the 2024/25 flu season. Following this first...
Sanofi has commenced shipping its influenza vaccines for the 2024/25 flu season, with deliveries starting on July 10 and continuing through October. The vaccines include options for various age groups and are designed to protect against the most prevalent flu strains. Sanofi emphasizes the importance of vaccination in preventing severe flu complications.
Read more →SNYDupixent approved in the EU as the first-ever targeted therapy for patients with COPD * First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landm
The European Medicines Agency has approved Dupixent as the first targeted therapy for adults with uncontrolled COPD characterized by raised blood eosinophils. This approval is based on positive results from landmark phase 3 trials that demonstrated improvements in lung function and reductions in exacerbations. Dupixent is expected to transform treatment options for over 200,000 patients in the EU suffering from this condition. The approval is a significant advancement after a decade of limited treatment options for COPD patients.
Read more →SNYSanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris
Sanofi and Biovac have forged a partnership to produce inactivated polio vaccines in Africa, marking a significant step towards regional vaccine manufacturing. This collaboration aims to fulfill the vaccination needs of over 40 African countries and positions Biovac as the continent's first IPV producer. By aligning with the Africa CDC's goal of increasing local vaccine production, this agreement underscores the importance of vaccines in combating diseases like polio post-COVID-19 pandemic disruptions.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – May 2024
Sanofi has released information regarding its total number of voting rights and shares as of May 31, 2024. The report indicates that there are 1,266,362,756 issued shares, with 1,411,203,841 real voting rights excluding treasury shares. The theoretical number of voting rights, which includes treasury shares, is noted at 1,426,537,484. This information is shared in compliance with regulations set forth by the French stock market authority.
Read more →SNYUpdate on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY
The FDA has extended its priority review of the supplemental Biologics License Application for Dupixent as an add-on treatment for adults with uncontrolled COPD characterized by type 2 inflammation. The new target action date is September 27, 2024, after the FDA requested additional efficacy analyses from pivotal trials. Sanofi and Regeneron remain confident that these analyses support Dupixent's approval, which is also under review in the EU and China, where a positive opinion has been recommended by the EMA. However, the safety and efficacy of Dupixent in this indication have yet to be fully evaluated by any regulatory authority.
Read more →SNYSanofi completes acquisition of Inhibrx, Inc. Paris
Sanofi has completed its acquisition of Inhibrx, Inc., gaining access to SAR447537, a promising treatment for alpha-1 antitrypsin deficiency (AATD). This acquisition emphasizes Sanofi's dedication to developing innovative therapies for rare diseases. Shareholders of Inhibrx approved the acquisition, which involved a total equity value of approximately $1.7 billion. Additionally, Inhibrx has spun off Inhibrx Biosciences as part of this transaction, which will begin trading under the ticker INBX.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - April 2024
Sanofi has released information regarding the total number of voting rights and shares as of April 30, 2024. The report details that there are 1,264,891,524 issued shares and 1,406,875,546 real voting rights, excluding treasury shares. It also states the theoretical number of voting rights including treasury shares is 1,423,541,154. This disclosure complies with French commercial regulations and is available on Sanofi's investor website.
Read more →SNYSanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a pro
Sanofi and Novavax have entered into a co-exclusive licensing agreement to co-commercialize a COVID-19 vaccine and develop flu-COVID-19 combination vaccines. This collaboration is aimed at providing broader access to Sanofi's COVID-19 vaccine and combining it with flu vaccines to enhance patient protection. Sanofi will also invest a minority equity stake in Novavax, underlining their commitment to vaccine innovation and public health. The partnership integrates Novavax's advanced recombinant protein technology and adjuvant with Sanofi's extensive expertise in vaccination commercialization.
Read more →SNYNew 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis * Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treat
Sanofi's frexalimab has shown promising results in a 48-week Phase 2 study for treating relapsing multiple sclerosis, demonstrating sustained efficacy and favorable tolerability. The treatment led to a sustained reduction in disease activity, with a reported very low annual relapse rate among participants. This strengthens the case for targeting CD40L in multiple sclerosis therapy and supports further development of frexalimab as a high-efficacy option. Results were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - March 2024
Sanofi has disclosed key information regarding the total number of its voting rights and shares as of March 31, 2024. The company stated it has a registered share capital of approximately €2.53 billion. The total number of issued shares stands at 1,264,891,324, with real voting rights numbering 1,406,934,286. The information complies with relevant French commercial regulations and is also available on Sanofi's website.
Read more →SNYW Kolumbii odbyła się pierwsza konferencja prasowa z udziałem kotów Zgodnie z założeniami programu promowania odpowiedzialnej adopcji firma Sanofi Consumer HealthCare zorganizowała pierwszą konferencję prasową z...
Sanofi Consumer HealthCare hosted its first press conference in Colombia to promote responsible cat adoption, introducing the Casa de Adopción de Amores Imposibles. The event aimed to encourage the adoption of neutered cats, particularly for individuals with allergies. The initiative saw significant community engagement, culminating in over 300 adoption applications.
Read more →SNYВ Колумбии прошла первая пресс-конференция с кошками В соответствии со своей целью содействия ответственному приему животных компания Sanofi Consumer HealthCare провела первую пресс-конференцию с самыми ...
Sanofi Consumer HealthCare held its first press conference in Colombia focused on cat adoption. The event aimed to promote the adoption of sterilized cats, addressing allergies related to Fel d1 protein. Over 300 applications for cat adoption were received, showcasing the initiative's success in raising awareness and interest in pet adoption.
Read more →SNYV Kolumbii se konala první tisková konference s kočkami V souladu se svým záměrem podporovat zodpovědnou adopci uspořádala společnost Sanofi Consumer HealthCare první tiskovou konferenci s těmi...
Sanofi Consumer HealthCare held its first press conference in Colombia to promote responsible cat adoption through its 'Adopt Your Allergy' campaign. The event featured the opening of the Casa de Adopción de Amores Imposibles, showcasing around 30 cats available for adoption. The initiative aims to help allergy sufferers adopt spayed cats, significantly reducing allergens.
Read more →SNYV Kolumbii sa konala prvá tlačová konferencia s mačkami V súlade so svojím cieľom podporovať zodpovedné adopcie usporiadala spoločnosť Sanofi Consumer HealthCare prvú tlačovú konferenciu s tými...
Sanofi Consumer HealthCare held its first press conference in Colombia to promote responsible cat adoption through the 'Adopt Your Allergies' campaign. The event featured around 30 cats and aimed to connect potential adopters with pets. The initiative resulted in over 300 adoption requests and highlights the impact of spaying on reducing allergy-causing proteins.
Read more →SNYDie erste Pressekonferenz mit Katzen fand in Kolumbien statt Im Einklang mit seinem Ziel, verantwortungsvolle Adoptionen zu fördern, hat Sanofi Consumer HealthCare die erste Pressekonferenz mit den zärtlichsten ...
Sanofi Consumer HealthCare hosted Colombia's first press conference featuring cats to promote responsible pet adoptions. The event introduced the 'Adoptionshaus der unmöglichen Lieben' initiative, aimed at increasing cat adoption rates. Attendees met around 30 cats, resulting in over 300 adoption applications. The campaign highlights the benefits of adopting neutered cats for allergy sufferers.
Read more →SNYLa première conférence de presse avec des chats a eu lieu en Colombie Conformément à son objectif de promotion de l'adoption responsable, Sanofi a tenu la première conférence de presse avec les hôtes les plus tendres et ...
Sanofi held Colombia's first press conference featuring cats to promote responsible adoption through its 'Adopt Your Allergies' campaign. The event introduced the 'Casa de Adopción de Amores Imposibles' and allowed attendees to interact with around 30 cats. The initiative aims to encourage the adoption of sterilized cats, significantly reducing allergy-causing proteins.
Read more →SNYThe first press conference with cats was held in Colombia In keeping with its purpose of promoting responsible adoption, Sanofi has held the first press conference with the most tender and furry hosts in the ...
Sanofi hosted Colombia's first press conference featuring cats to promote its 'Adopt Your Allergies' initiative. The event, held in partnership with the Adopta No Compres Foundation, aimed to encourage the adoption of spayed cats, reducing allergens for allergy sufferers. Over 300 adoption requests were made during the event, highlighting its success.
Read more →SNYPrimera conferencia de prensa con gatos celebrada en Colombia Siguiendo con su propósito de promover la adopción responsable, Sanofi Consumer HealthCare ha celebrado la primera rueda de prensa con los...
Sanofi Consumer HealthCare hosted Colombia's first cat adoption press conference to promote responsible pet adoption. The event introduced the 'Casa de Adopción de Amores Imposibles' and aimed to encourage the adoption of sterilized cats for allergy sufferers. Attendees met around 30 cats, resulting in over 300 adoption applications.
Read more →SNYSanofi - AGM 30.04.2024 - Availability of Preparatory documents
Sanofi has announced the details for its Combined General Meeting scheduled for April 30, 2024, at the Palais des Congrès in Paris. Shareholders are invited to attend, and preparatory documents will be available in compliance with legal regulations. The notice of the meeting has been published, providing information regarding agenda, draft resolutions, and voting procedures. Shareholders can request additional documents by following outlined procedures before the deadline.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - February 2024
Sanofi has released information regarding the total number of voting rights and shares as of February 29, 2024, in compliance with French regulations. The company reported a total of 1,264,891,324 issued shares and 1,406,985,229 real voting rights, which suggests a robust governance structure. This data aims to enhance transparency for investors and shareholders in the French market.
Read more →SNYNew Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and symptoms
The Phase 2b STREAM-AD study results for amlitelimab indicate sustained improvement in atopic dermatitis symptoms for up to 28 weeks in adults. Positive responder rates were noted in patients both on treatment and those withdrawn from treatment. The investigational drug demonstrated a favorable safety profile consistent with earlier study phases. These findings support further investigation in a larger Phase 3 clinical trial aimed at assessing double dosing every 12 weeks.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - January 2024
Sanofi has released information regarding its total number of voting rights and shares for January 2024, in compliance with French regulations. The document indicates that as of January 31, 2024, Sanofi has issued 1,264,803,301 shares, with 1,406,897,400 real voting rights. Additionally, the theoretical number of voting rights, including treasury shares, is noted as 1,423,143,048. This information is part of the company's ongoing commitment to transparency in its investor communications.
Read more →SNYPhase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS High-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain les
Recent Phase 2 trial results published in the New England Journal of Medicine indicate that frexalimab, a second-generation investigational anti-CD40L antibody developed by Sanofi, shows high efficacy in treating relapsing multiple sclerosis (MS). The study reported an 89% reduction in new gadolinium-enhancing T1 brain lesions among patients receiving the high dose of frexalimab compared to placebo. With both high and low doses leading to significant reductions in disease activity, the findings have broad implications for the MS community. Sanofi is proceeding with Phase 3 clinical trials based on these encouraging results.
Read more →SNYPeer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses Paris
Sanofi has launched a new global initiative called 'Cancer & Work: Acting Together' aimed at supporting employees impacted by cancer and critical illnesses. This program provides extensive social, emotional, and financial support, including job security and salary continuation for twelve months for affected employees. Additionally, it offers access to a network of volunteer colleagues trained to assist employees throughout their treatment and recovery process. Designed to enhance inclusivity and accommodate the needs of those affected, the program reflects Sanofi’s broader commitment to Diversity, Equity, and Inclusion (DE&I).
Read more →SNYDupixent FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) * Approval based on Phase 3 EoE KIDS trial showing a greater proportion of
The FDA has approved Dupixent (dupilumab) for use in children aged 1 to 11 years with eosinophilic esophagitis (EoE), making it the first and only treatment specifically for this age group. This approval comes after positive results from the Phase 3 EoE KIDS trial, which demonstrated significant efficacy in achieving disease remission. Dupixent addresses important unmet medical needs, targeting the root cause of EoE-related complications and providing new hope for children struggling with this chronic condition.
Read more →SNYSanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi s portfolio growth strategy and complements 30-y
Sanofi has announced its acquisition of Inhibrx, Inc., aiming to enhance its pipeline with INBRX-101, a potential treatment for Alpha-1 Antitrypsin Deficiency. This human recombinant protein is expected to improve dosing frequency and provide better management of the rare disease. The acquisition aligns with Sanofi's strategy to bolster its presence in rare diseases, particularly in immune-mediated respiratory conditions. The deal is pending the spin-off of non-INBRX-101 assets and requires regulatory approvals and shareholder consent.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - December 2023
On December 31, 2023, Sanofi reported its total number of voting rights and shares in compliance with French commercial regulations. The company revealed that it has issued 1,264,799,969 shares, resulting in 1,410,152,297 real voting rights and a theoretical total of 1,423,602,685 voting rights, including treasury shares. This information is part of Sanofi's regular regulatory disclosures and can be accessed on their official website. The disclosure reflects standard corporate governance practices to inform stakeholders about shareholding and voting dynamics.
Read more →SNYBrian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee Paris, January 9 2024 . Brian Foard, a healthcare industry veteran and Sanofi leader in the U.S., has
Brian Foard has been appointed as the Head of the Specialty Care Global Business Unit and as a member of Sanofi's Executive Committee, effective immediately. He brings over 20 years of experience in specialty biopharma, having served as Head of Specialty Care North America and U.S. Country Lead prior to this role. Foard was instrumental in the successful global launch of Dupixent and aims to advance Sanofi's strategy to become a leading immunology company. His appointment reflects Sanofi's focus on innovation and commitment to improving patient lives globally.
Read more →SNYSanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint CARMEN-LC03 trial did not meet dual primary endpoint of improving progression
Sanofi has announced the discontinuation of its clinical development program for tusamitamab ravtansine following the failure of the Phase 3 CARMEN-LC03 trial to meet its dual primary endpoints. The Independent Data Monitoring Committee reported that the drug did not demonstrate improved progression-free survival compared to docetaxel. Although there was a noted trend towards improved overall survival, the lack of significant efficacy in the primary endpoint led to the decision. Sanofi will continue exploring the potential of tusamitamab-based antibody-drug conjugates in various cancer types.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - November 2023
Sanofi has provided an update regarding the total number of voting rights and shares as of November 30, 2023. The total number of issued shares is reported at 1,264,791,127, with the number of real voting rights at 1,412,747,285. The theoretical number of voting rights, including treasury shares, stands at 1,423,613,133. This information is mandated by French commercial regulations and is accessible on Sanofi's official website.
Read more →SNYR&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including S
Sanofi recently hosted an Investor R&D Day in New York, focusing on its robust pipeline of potential blockbuster drugs. The company is emphasizing 12 new molecular entities, with a significant increase in Phase 3 studies planned from 2023 to 2025. Sanofi aims to leverage its leadership in immunology by introducing innovative therapies across various conditions. CEO Paul Hudson expressed confidence in the current portfolio and the commitment to deliver sustainable growth through 2030 and beyond.
Read more →SNYDupixent significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease * NOTUS tr
Sanofi and Regeneron's Dupixent has shown positive results in the NOTUS Phase 3 trial for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations by 34%. These findings corroborate earlier results from the BOREAS trial, driving plans for expedited FDA submission. While the trial results are promising, the safety profile is under scrutiny, as indicated by the occurrence of adverse events. Both companies aim to address the high unmet need in COPD treatment, with Dupixent potentially being the first biologic therapy approved for this condition.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - October 2023
Sanofi released a report detailing the total number of voting rights and shares as of October 31, 2023. The company has a registered capital of €2,529,036,828 and reported a total of 1,264,791,127 issued shares. The number of real voting rights, excluding treasury shares, stands at 1,412,765,443, while the theoretical number of voting rights, including treasury shares, is 1,423,631,291. This information complies with French regulations and is accessible on Sanofi's official website.
Read more →SNYMarca número 1 no combate as dores lança fórmula que promete revolucionar o mercado de analgésicos Dorflex, marca de Consumer Healthcare na Sanofi, entrega mais uma vez uma solução baseada em ciência para que o brasileiro possa ir em frente sem se...
Sanofi's Dorflex brand has launched Dorflex MAX, a new pain relief formula with double the muscle relaxant and analgesic in one tablet. This product, developed over five years, aims to address intense pain that affects daily activities. The brand continues its campaign promoting self-care and resilience among Brazilians.
Read more →SNYSanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's...
Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations dedicated to addressing health disparities in underserved U.S. communities. Each organization will receive $50,000 and access to Sanofi's resources to enhance their initiatives. The awards were presented at the Trust, Inclusion, and Equity Summit, highlighting the importance of community-driven health equity solutions.
Read more →SNYSanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S. Nationwide storytelling movement to showcase diverse voices of the type 1 diabetes community, including internationally recognized stars Usher, Robin ...
Sanofi has launched 'The 1 Pledge' movement, a nationwide campaign aimed at promoting early screening for type 1 diabetes. The initiative features celebrities like Usher and Robin Arzón, who share personal stories to emphasize the importance of early detection. The campaign encourages families to pledge to get screened, aiming to prepare them for potential diagnoses.
Read more →SNY▼ -19.1%on this newsshared move
Sanofi Enters Next Chapter of Play to Win Strategy Increases investments in its pipeline to fully realize long-term growth potential, bolstered by successful launches and R&D progress. Launches strategic co
Sanofi has announced its commitment to increasing R&D investments as part of its Play to Win strategy, aimed at enhancing long-term growth and shareholder value. The move includes the intention to separate its Consumer Healthcare Business to allow focused management of its Biopharma segment. Despite maintaining its financial guidance for 2023, the company anticipates some pressure on earnings per share due to increased tax rates. Sanofi will host an R&D Day in December 2023 to discuss its pipeline and future growth prospects in more detail.
Read more →SNYMedia Update Sanofi and Regeneron provide update on Dupixent (dupilumab) sBLA for Chronic Spontaneous Urticaria Paris and Tarrytown, N.Y.
Sanofi and Regeneron have announced that the FDA issued a Complete Response Letter (CRL) concerning the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in treating chronic spontaneous urticaria (CSU). The CRL specifies that additional efficacy data is necessary for approval but does not indicate any safety or manufacturing issues. An ongoing clinical trial is expected to provide these required data by late 2024. The companies are focused on collaborating with the FDA to further develop Dupixent for patients with CSU.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - September 2023
Sanofi has released information regarding the total number of voting rights and shares as of September 30, 2023. The company reported a total of 1,264,762,373 issued shares, with 1,412,756,915 real voting rights available when excluding treasury shares. The theoretical number of voting rights, which includes treasury shares, stood at 1,423,659,154. This information is made available in compliance with French commercial regulations and can be accessed on Sanofi's official investor website.
Read more →SNYLate-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Patients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Ar
Sanofi presented promising Phase 2b data for amlitelimab at the EADV 2023 Congress, showing significant improvements in atopic dermatitis symptoms among patients inadequately controlled by topical treatments. The study demonstrated up to a 61.5% reduction in the Eczema Area and Severity Index (EASI) score for patients receiving amlitelimab. The results support the drug's potential as a best-in-class therapy, and a Phase 3 trial is expected to begin in early 2024. The safety profile was reported as favorable, with common treatment-emergent adverse events similar to those observed in placebo.
Read more →SNYSanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approxim
Sanofi has entered into a collaboration with Janssen Pharmaceuticals to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli (ExPEC). This vaccine, currently in Phase 3 trials, aims to address the rising prevalence of sepsis in older adults, driven by this bacterial pathogen. Both companies will share funding responsibilities, with Sanofi committing $175 million upfront. Although the partnership seeks to improve public health outcomes and reduce associated healthcare costs, it remains contingent on regulatory approvals and involves risks related to development and commercialization.
Read more →SNYSanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change Paris
Sanofi announced significant initiatives aimed at supporting vulnerable communities affected by climate change during the United Nations 78th General Assembly. The company pledged nearly EUR 40 million through its philanthropic organization, Foundation S, to enhance adaptation and health resilience in these communities. Additionally, Sanofi is working towards achieving carbon neutrality by 2030, alongside plans to invest over EUR 450 million in environmentally sustainable practices. Their efforts reflect a commitment to not only mitigate environmental impacts but also improve healthcare access worldwide.
Read more →SNYSanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu In collaboration with Ice-T, Sanofi has debuted a trailer for this year's newest thriller – The Season. The trailer taps into suspenseful movie...
Sanofi has launched a new campaign featuring rapper Ice-T to promote flu vaccination among older adults. The campaign highlights the importance of higher-dose flu vaccines, particularly for those with chronic health conditions. The initiative aims to educate and encourage at-risk populations to consult healthcare providers about their vaccination options. This year's flu season may see a resurgence, making vaccination crucial.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - August 2023
Sanofi has provided an official update concerning the total number of voting rights and shares as of August 31, 2023. The report states that the total number of issued shares is 1,264,525,904, with 1,412,690,364 real voting rights and 1,423,592,603 theoretical voting rights, including treasury shares. This information is disclosed in compliance with French regulations and is available on Sanofi's investor relations website.
Read more →SNYSanofi announces changes to its Executive Committee Paris, August 31 st , 2023 . Sanofi announces the following changes to its Executive Committee: Houman Ashrafian is appointed as Head of Research & Develo
Sanofi has announced significant changes to its Executive Committee, appointing Houman Ashrafian as the new Head of Research & Development, along with Madeleine Roach and Emmanuel Frenehard in leadership roles. These appointments aim to reinforce Sanofi's commitment to innovation and improve operational efficiency. The company has highlighted a robust pipeline of nearly 80 clinical programs and will continue its strategy of developing first or best-in-class medicines. The new leadership team is expected to enhance Sanofi's position as a science-driven and innovative leader in the biopharmaceutical industry.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - July 2023
Sanofi has released information regarding the total number of voting rights and shares as of July 31, 2023. The company reported a total of 1,264,518,414 issued shares, with 1,412,825,313 real voting rights that exclude treasury shares. Additionally, the theoretical number of voting rights, which includes treasury shares, stands at 1,423,727,552. This disclosure complies with French commercial regulations and is available on the Sanofi website for investor access.
Read more →SNYU.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus (nirsevimab-alip) to protect infants against RSV disease * Recommendation for use in all infants below 8 months of age follows ear
The U.S. CDC Advisory Committee unanimously recommended the routine use of Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) to prevent respiratory syncytial virus (RSV) disease in infants under 8 months of age. This decision follows a unanimous vote to include Beyfortus in the Vaccines for Children program, enhancing access to the treatment for vulnerable populations. Beyfortus, approved by the FDA, offers rapid protection against RSV and will be available in the U.S. ahead of the upcoming RSV season. The recommendation underscores the urgency of addressing RSV risks for young infants.
Read more →SNYTABLE OF CONTENTS 2 HALF-YEAR MANAGEMENT REPORT 38 A Significant events of the first half of 2023 38 B Progress on implementation of the Corporate Social Responsibility strategy 41 C Events subsequent to
Sanofi's half-year management report for 2023 highlights several strategic advancements, including the acquisition of Provention Bio for $2.8 billion to bolster its diabetes treatment portfolio. The FDA's approval of ALTUVIIIOTM marks a significant milestone in hemophilia A therapy, while Dupixent received approvals for treating severe conditions in young children and adults. Despite positive developments, the company reported a risk regarding ongoing Zantac litigation, although it has been cleared of liability in this case. Overall, Sanofi is advancing its strategy with a focus on innovative product development.
Read more →SNYSanofi to acquire Qunol , a fast-growing U.S. brand in the healthy aging segment * Transaction brings Qunol , a trusted, profitable double-digit growth and market-leading brand in health & wellness to Sanof
Sanofi has announced its agreement to acquire Qunol, a U.S.-based brand specializing in health and wellness products, particularly in the healthy aging segment. This acquisition aims to enhance Sanofi's Consumer Healthcare Vitamin, Mineral and Supplements category, leveraging Qunol's strong market presence and product efficacy. The deal is set to close in Q3 2023, pending regulatory approvals, and is expected to unlock growth opportunities for Sanofi in the U.S. and beyond. This strategic move is aligned with growing consumer demand for health solutions targeting chronic conditions.
Read more →SNYSanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact After making strides in environmental sustainability and social impact commitments, Sanofi Consumer Healthcare North America is pleased to announce...
Sanofi Consumer Healthcare North America has achieved B Corp Certification, becoming the first large consumer healthcare company to do so. This certification reflects their commitment to environmental sustainability and social impact, including significant reductions in plastic packaging and greenhouse gas emissions. The company aims for carbon neutrality by 2030 and gender parity in leadership by 2025.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – June 2023
Sanofi provided a report detailing the total number of voting rights and shares as of June 30, 2023. The registered share capital is €2,521,494,572, with a total of 1,262,388,181 issued shares. The report also includes the number of real voting rights (1,410,356,237) and the theoretical number of voting rights (1,421,258,476), noting the exclusion of treasury shares in the former figure. This information is compliant with French regulations and is accessible on the company's official website.
Read more →SNYFDA approves Beyfortus (nirsevimab-alip) to protect infants against RSV disease Beyfortus is the first monoclonal antibody approved to protect all infants through their first RSV season Across all clinical
The FDA has approved Beyfortus (nirsevimab-alip), a monoclonal antibody developed by Sanofi and AstraZeneca, for the prevention of RSV in infants. This breakthrough aims to protect newborns during their first RSV season and is indicated for children up to 24 months at risk of severe disease. The FDA approval follows positive recommendations based on extensive clinical trial data, highlighting the drug's high efficacy and safety profile. Beyfortus is expected to be available in the U.S. before the upcoming RSV season.
Read more →SNYALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids data confirm the efficacy and safety profile of AL
ALTUVIIIO, a first-in-class factor VIII replacement therapy, has shown promising results in the Phase 3 XTEND-Kids study for children under 12 with severe hemophilia A. Presented at ISTH 2023, the data confirmed effective bleed protection and no inhibitor development, supporting its efficacy for once-weekly prophylaxis. This advancement could significantly reduce treatment burden for pediatric patients and improve their quality of life. ALTUVIIIO is also backed by multiple designations from regulatory authorities, enhancing its profile in hemophilia management.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - May 2023
Sanofi has provided an update regarding its total number of voting rights and shares as required by French law. As of May 31, 2023, the company has issued 1,262,376,281 shares, with a theoretical number of voting rights amounting to 1,421,354,711, which includes treasury shares. This information is part of compliance under the French Commercial Code and is accessible on Sanofi's official investor website.
Read more →SNYFDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants Nirsevimab would be the first immunization specifically designed to protect all infants thr
The FDA Antimicrobial Drugs Advisory Committee unanimously recommended nirsevimab, marking it as the first immunization specifically designed to protect infants against respiratory syncytial virus (RSV). This recommendation was founded on a favorable benefit-risk assessment following a robust clinical development program. If approved, nirsevimab would potentially be available before the start of the 2023-2024 RSV season, addressing a critical healthcare need as RSV remains a leading cause of hospitalization in infants. The drug shows promise, with demonstrated efficacy across pivotal clinical trials.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – April 2023
Sanofi has released information regarding its total number of voting rights and shares as of April 30, 2023. The report indicates a registered share capital of €2,521,494,572 with a total of 1,261,068,723 issued shares. It also details the number of real and theoretical voting rights, amounting to 1,406,078,073 and 1,418,273,543 respectively. This disclosure complies with French commercial regulations.
Read more →SNYNirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab s consistent and high efficacy against infant hospitalizat
The HARMONIE Phase 3b clinical trial indicates that nirsevimab significantly reduces RSV-related hospitalizations in infants under 12 months by 83.21%. Conducted across multiple European countries, the trial involved over 8,000 participants and illustrated nirsevimab's efficacy in a real-world setting during the RSV season. Moreover, nirsevimab maintained a favorable safety profile comparable to previous studies, marking its potential as an impactful preventative measure against RSV in pediatric populations.
Read more →SNYSanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS
COMBINED GENERAL MEETING OF MAY 25, 2023 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday May 25, 2023 at 2:30 p.m. (CET) at the Palais des Congrès – Grand Amphithéâtre – 2, place de la Po
Read more →SNYSanofi completes acquisition of Provention Bio, Inc. Paris, April 27 2023. Sanofi announced today the completion of its acquisition of Provention Bio, Inc . ( Provention Bio ). The acquisition adds TZIELD (
Sanofi has finalized its acquisition of Provention Bio, Inc., which includes the innovative diabetes therapy TZIELD (teplizumab-mzwv). This move strengthens Sanofi's position in General Medicines, especially in addressing immune-mediated diseases. The acquisition was approved after all tender conditions were met, and Provention Bio will now operate as a wholly owned subsidiary under Sanofi. TZIELD is recognized as the first therapy approved to delay the onset of stage 3 type 1 diabetes, showcasing Sanofi's commitment to enhancing its therapeutic portfolio.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - March 2023
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYNirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements Modification of existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of nirsevimab and enhanced agi
Sanofi has announced a simplification of its contractual agreements related to the development and commercialization of Beyfortus (nirsevimab) in the U.S. The new arrangements give Sanofi full commercial control over nirsevimab, as Sobi terminates its participation agreement with AstraZeneca. Simultaneously, Sanofi entered into a direct royalty agreement with Sobi to share a portion of U.S. net sales. The commitment remains to make Beyfortus available for infants during the 2023/24 RSV season, while existing international agreements with AstraZeneca will continue to govern operations outside the U.S.
Read more →SNYTwo fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia Both Phase 3 studies achieved their primary and sec
Sanofi's fitusiran has shown promising results in two Phase 3 studies published in major medical journals, highlighting its efficacy in treating hemophilia A and B. The studies demonstrated that fitusiran significantly reduces annualized bleeding rates by 90% compared to standard on-demand treatments. The therapy offers a new prophylactic option that may transform patient care with far fewer injections required annually. Sanofi plans to share further data on this investigational therapy later this year, signaling ongoing commitment to advancing hemophilia treatment options.
Read more →SNYSanofi cuts U.S. list price of Lantus , its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance Paris
Sanofi has announced a significant reduction in the list price of its most-prescribed insulin, Lantus, cutting it by 78% and capping out-of-pocket costs at $35 for all patients with commercial insurance. This change, effective January 1, 2024, builds on previous affordability initiatives, including a launch of an unbranded biologic at a lower cost. The company emphasizes its dedication to providing affordable medications and aims to transform the U.S. insulin market to ensure no patient pays more than the set cap for a monthly supply.
Read more →SNYSanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) Paris and Red Bank, N.J.
Sanofi has announced its agreement to acquire Provention Bio for $25 per share, valuing the company at approximately $2.9 billion. This acquisition aims to enhance Sanofi's portfolio with TZIELD, the first approved therapy to delay Stage 3 type 1 diabetes in patients with Stage 2 T1D. The deal reflects a strategic alignment between Sanofi's focus on immune-mediated diseases and its commitment to developing innovative therapies. Sanofi expects to complete the acquisition in the second quarter of 2023, pending customary conditions and regulatory approvals.
Read more →SNYDupixent (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review * More than 300,000 people in the U.S. suffer from CSU that is inadequ
Sanofi announced that the FDA has accepted the supplemental Biologics License Application for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and older. This condition affects many patients who remain uncontrolled on current H1 antihistamine treatments. The FDA is set to make a decision on this application by October 22, 2023. The application is backed by data from two Phase 3 trials assessing the efficacy and safety of Dupixent in patients with uncontrolled CSU.
Read more →SNYCompleted XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO TM to redefine expectations for treatment of children 12 years of age with hemophilia A Paris
The XTEND-Kids Phase 3 study has successfully evaluated the once-weekly administration of ALTUVIIIO for children under 12 years with severe hemophilia A. The trial met its primary endpoint of safety, as no FVIII inhibitors were detected among the participants. With a significant number of children demonstrating positive outcomes over nearly a year of treatment, this completion paves the way for regulatory submission in the European Union. ALTUVIIIO's innovative approach could potentially redefine treatment expectations for young patients with this condition.
Read more →SNYFDA approves once-weekly ALTUVIIIO , a new class of factor VIII therapy for hemophilia A that offers significant bleed protection Paris and Stockholm
The FDA has approved ALTUVIIIO, a novel once-weekly therapy for patients with hemophilia A, offering significant improvements in bleed protection. This first-in-class therapy maintains high factor activity levels, reducing the annual bleeding rates substantially compared to prior treatments. With a simplified dosing regimen, ALTUVIIIO aims to enhance the lives of individuals living with hemophilia A, marking a significant advancement in treatment options. The drug is expected to be commercially available in the U.S. in April, with further regulatory submissions anticipated in Europe later this year.
Read more →SNYSanofi, market leader in DTaP pediatric combination vaccines, with 55.4 million doses used in 2021
Lyon, France, Feb. 23, 2023 (GLOBE NEWSWIRE) -- A new study shows that Sanofi is the global market leader among aP-based pediatric combination vaccines with a 74.7% share, leading the move from DTwP vaccines to DTaP-based combination vaccines. The study analyzes global volumes an
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – January 2023
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYSanofi announces change in R&D leadership Paris
Sanofi has announced that Dr. John Reed, the Global Head of R&D, will be leaving the company for a new opportunity. Dr. Reed has been instrumental in the company's R&D transformation since joining in 2018, enhancing their focus on innovative therapeutics. Dr. Dietmar Berger will lead the R&D team on an interim basis as the search for Reed's successor begins. The company looks forward to upcoming milestones, including new drug launches and scientific readouts that align with their strategy to enhance patient care.
Read more →SNYNEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A Paris and Stockholm
The New England Journal of Medicine published Phase 3 data on efanesoctocog alfa, a once-weekly treatment for hemophilia A. The study indicates that it can deliver normal to near-normal factor activity levels for most of the week. Efanesoctocog alfa met key efficacy endpoints, showing significant improvements in physical health and pain. The FDA is currently reviewing this investigational therapy, with a decision expected by February 28, 2023.
Read more →SNYPositive Dupixent (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine * Dupixent 300 mg weekly showed significant histologica
Recent Phase 3 trial results published in the New England Journal of Medicine confirmed that Dupixent (dupilumab), administered weekly at 300 mg, significantly reduces symptoms in patients with eosinophilic esophagitis (EoE). The trial demonstrated improvements in swallowing and histological metrics, with effects lasting up to one year. Dupixent has been approved by the FDA for individuals aged 12 and older with EoE and is currently under review by the European Medicines Agency (EMA). The findings underline Dupixent's effectiveness and potential to improve the quality of life for EoE patients.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – December 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYSanofi: Information concerning the total number of voting rights and shares November 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYDupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis * Approval based on direct-to-Phase 3 program showing more than three times as ma
Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Paris and Tarrytown, N.Y. Dec. 15, 2022 The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Uni
Read more →SNYAcoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa * Positive Phase II/III study results support acoziborole s potential in treatment for dead
Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa Geneva, Kinshasa, Paris November 30, 2022. The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phas
Read more →SNYEuropean Commission approves Enjaymo (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved for hemo
European Commission approves Enjaymo (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has granted marketing authorization for Enjaymo (sutimlimab) for the treatment of hemolytic
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – October 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYSanofi and GSK s next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe Stro
Sanofi and GSK s next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission Paris, November 10, 2022. After the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, t
Read more →SNYEuropean Commission grants first approval worldwide of Beyfortus (nirsevimab) for prevention of RSV disease in infants Beyfortus is the first and only broadly protective option against RSV for newborns and
European Commission grants first approval worldwide of Beyfortus (nirsevimab) for prevention of RSV disease in infants Paris, November 4, 2022. The European Commission has approved Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - September 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYDupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old * 68% of children on a hi
Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old Paris and Tarrytown, N.Y. October 11, 2022. Late-breaking positive results from a Phase 3 trial e
Read more →SNYDupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program con
Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nod
Read more →SNYCHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants Recommendation is based on the Beyfortus clinical trial program which demonstrated protection against medically at
CHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants Paris, September 16, 2022. The European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus (nirsevimab) for the preven
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - August 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYEvolution of the Board of Directors Paris
Evolution of the Board of Directors Paris, September 5, 2022. The Board of Directors of Sanofi met on September 2, 2022 and unanimously appointed Fr d ric Oud a as Censeur (non-voting member) of the Board with immediate effect. The appointment of Fr d ric Oud a as a director w
Read more →SNYFDA grants priority review to efanesoctocog alfa for people with hemophilia A The FDA decision date for efanesoctocog alfa, an investigational factor VIII therapy, is set for
FDA grants priority review to efanesoctocog alfa for people with hemophilia A August 30, 2022 The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A,
Read more →SNY▼ -5.9%on this news
Sanofi provides update on amcenestrant clinical development program PARIS
Sanofi provides update on amcenestrant clinical PARIS, August 17, 2022. Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision is based on the outcome of a prespecified i
Read more →SNYMedia Update Paris
Paris, August 11, 2022. In response to the recent highly speculative news flow regarding the U.S. Zantac litigation at a time when there have not been any material developments, Sanofi remains confident in its legal defenses and wishes to make the following statement, consisten
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – July 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock mark
Read more →SNYSanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China Collaboration to accelerate the development and access of oncology me
Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China Paris, August 4, 2022. Sanofi and Innovent Biologics (HKEX: 1801.HK, Innovent ) announced a collaboration to bring innovative medicines to
Read more →SNYTABLE OF CONTENTS 2 HALF-YEAR MANAGEMENT REPORT 40 A Significant events of the first half of 2022 40 B Progress on implementation of the Corporate Social Responsibility strategy 44 C Events subsequent to
2 HALF-YEAR MANAGEMENT REPORT 40 A Significant events of the first half of 2022 40 B Progress on implementation of the Corporate Social Responsibility strategy 44 C Events subsequent to June 30, 2022 48 D Consolidated financial statements for the first half of 2022 49 E
Read more →SNYDupixent (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis * First and only investigational Phase 3 trial to show positive results in these youn
Dupixent (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis Paris and Tarrytown, N.Y. July 14, 2022 A Phase 3 trial assessing the investigational use of Dupixent (dupilumab) in children aged 1 to 11 years with eosinop
Read more →SNYFitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis A median annualized bleeding rate (ABR) of 0
Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis 2022 Positive data from the Phase 3 ATLAS-PPX study evaluating the efficacy and safety of once-monthly fitusiran (80
Read more →SNYSanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries * Medicines, including insulin, to be available in 40 lower-income countries * Investment fund established to he
Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries Paris July 4, 2022 Sanofi Global Health announces the launch of Impact , a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk po
Read more →SNY▼ -5%on this newsshared move
Media Update Patient enrollment of phase III tolebrutinib trials paused in the U.S. Paris
Patient enrollment of phase III tolebrutinib trials paused in the U.S. Paris, June 30, 2022. The U.S. Food and Drug Administration (FDA) has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis on partial clinical hold. As a result, new enroll
Read more →SNY▲ +6%on this news
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against sympto
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine Paris, June 24, 2022. Sanofi and GSK today announce positive data from their vaccine trial which evaluated an adjuvanted bivalent D614 and Beta (B.1.351) vaccine candid
Read more →SNYSanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron Next-generation booster vaccine candidate delivers immune boost in adults primed wi
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron Paris June 13, 2022 Sanofi today reports data from two trials, VAT02 Cohort 2 and COVIBOOST VAT013, conducted with its new next-generation COVID-19 booster
Read more →SNYFDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Dupixent is the first and only biologic medicine approved to trea
FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Tarrytown, N.Y. June 7, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 months to
Read more →SNYFDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA Designation is b
FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A June 1, 2022 The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A, a rare an
Read more →SNYUpdate on Cialis Rx-to-OTC Switch Actual Use Trial Paris .
Cialis Rx-to-OTC Switch Actual Use Trial Paris. May 30, 2022. The U.S. Food and Drug Administration has informed Sanofi that its planned Actual Use Trial (AUT) to support the Rx-to-OTC switch for Cialis (tadalafil) has been placed on clinical hold due to matters surrounding the
Read more →SNYFDA approves Dupixent (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis * Dupixent is the first and only medicine indicated to treat eosinophilic esophag
FDA approves Dupixent (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis Paris and Tarrytown, N.Y. May 20, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) 300 mg weekly to treat patients wi
Read more →SNYQ1 2022 Change IFRS net sales reported 9,674m +12.6% IFRS net income reported 2,009m +28.3% IFRS EPS reported 1.61 +28.8% Business operating income 3,065m +16.2% Changes in net sales are expressed at constant exchange ra
Q1 2022 Change IFRS net sales reported 9,674m +12.6% IFRS net income reported 2,009m +28.3% IFRS EPS reported 1.61 +28.8% Business operating income 3,065m +16.2% Changes in net sales are expressed at constant exchange rates (CER)
Read more →SNYNew nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract i
New nirsevimab data analyses reinforce efficacy against RSV Paris, May 11, 2022. Results from a prespecified pooled analysis of the pivotal Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% (95% CI 65.9 to 8
Read more →SNYSanofi teams up with McLaren Racing to accelerate industrial excellence Paris
Sanofi teams up with McLaren Racing to accelerate industrial excellence Paris, April 26, 2022. Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company s ambition to attain world-class stan
Read more →SNYPositive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine Results published today in the New England Journal of Medicine showe
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine PARIS April 14, 2022 - Positive results from the Phase 1/2 dose-finding study evaluating the safety, pharmacokinetics and clinical activity
Read more →SNYFDA accepts Dupixent (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis If approved, Dupixent would be the first medicine available in the U.S. indicated to tr
FDA accepts Dupixent (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis Paris and Tarrytown, N.Y., April 4, 2022. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Appl
Read more →SNYEUROAPI listing on Euronext Paris expected on
EUROAPI listing on Euronext Paris expected on May 6, 2022 Paris, April 1, 2022. Sanofi announced today that the French Autorit des march s financiers (AMF) has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regul
Read more →SNYInformation Statement DISTRIBUTION OF SHARES OF EUROAPI TO THE SHAREHOLDERS OF SANOFI This information statement is intended to provide shareholders of Sanofi ( Sanofi ) in specified jurisdictions other than France (as s
Information Statement DISTRIBUTION OF SHARES OF EUROAPI TO THE SHAREHOLDERS OF SANOFI information statement is intended to provide shareholders of Sanofi ( Sanofi ) in specified jurisdictions other than France (as set forth under Notice to Prospective Shareholders of EUROAPI ,
Read more →SNYSanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines Paris
Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to Paris, March 31, 2022. Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes (the Notes ). It comprises an inaugural issue of sustaina
Read more →SNYLate-breaking Phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis * Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly thre
Late-breaking Phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis Paris and Tarrytown, N.Y. March 26, 2022. Detailed positive results from the Phase 3 PRIME2 trial evaluating the safety and efficacy of Dupixent (dupi
Read more →SNYSanofi and Seagen Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates * Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of can
Sanofi and Seagen Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Paris. March 16, 2022. Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADC
Read more →SNYSanofi recognized by S&P as one of the most sustainability-committed companies Paris
Sanofi recognized by S&P as one of the most sustainability-committed companies Paris, March 8, 2022. Sanofi was today recognized as one of the most sustainability-committed companies in an ESG Evaluation (Environment, Social, Governance) performed by Standard & Poor s Global Ra
Read more →SNYLate-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria * In this Phase 3 trial, Dupixent added
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria Paris and Tarrytown, N.Y., February 26, 2022. Detailed results from a Phase 3 trial showed that adding Dupixent (
Read more →SNYUpdate on ongoing Dupixent (dupilumab) chronic spontaneous urticaria Phase 3 program * In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in an interim
Update on ongoing Dupixent (dupilumab) chronic spontaneous urticaria Phase 3 program PARIS and TARRYTOWN, N.Y., February 18, 2022. A Phase 3 trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous urticaria (CSU), who were refractory to omali
Read more →SNYFDA approves Enjaymo (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease * Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to h
FDA approves Enjaymo (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease Paris, February 4, 2022. The U.S. Food and Drug Administration (FDA) has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemol
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) CHMP recommends approval of Dupixent (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation * Recommendation based on pivotal tr
CHMP recommends approval of Dupixent (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation PARIS and TARRYTOWN, N.Y. January 31, 2022 - The European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has adopted a positiv
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis * Dupixent is the first and only medicin
Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis PARIS and TARRYTOWN, N.Y. January 19, 2022 A second Phase 3 trial evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic t
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines * Collaborative efforts aim to a
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines PARIS, OXFORD, and BOSTON January 7, 2022 Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to dev
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi PARIS
Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi PARIS December 16, 2021 - On December 15, 2021, the Board of Directors appointed Gilles Schnepp, an independent director of Sanofi, as Chairman of the Appointments, Governance and
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates * Sanofi confirms Vaccines
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates PARIS December 1, 2021 Today, Sanofi hosts a hybrid Vaccines Investor Event with key members of the Vaccines leadership team to discuss how the
Read more →SNYSanofi invests $180 million equity in Owkin s artificial intelligence and federated learning to advance oncology pipeline Combined efforts will work to build robust disease models while preserving privacy of large data s
Sanofi invests $180 million equity in Owkin s artificial intelligence and federated learning to advance oncology pipeline PARIS November 18, 2021 Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi completes acquisition of Kadmon Paris
Sanofi completes acquisition of Kadmon Paris November 9, 2021 - Sanofi announced today the completion of its acquisition of Kadmon Holdings, Inc. The acquisition further strengthens growth and expansion for the General Medicines portfolio. Shareholders of Kadmon common stock v
Read more →SNYSecond Dupixent (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease Dupixent 300 mg weekly significantly im
Second Dupixent (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease PARIS and TARRYTOWN, N.Y. October 25, 2021 Results from a second Phase 3 trial assessing the inv
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 * One-year results from Phase 2b e
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented PARIS October 13, 2021 - Sanofi s investigational oral Bruton s tyrosine kinase (BTK) inhibitor, tolebrutinib, demonstrated favorable one-year tolerability in a Phase 2
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe a
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis PARIS September 30, 2021 Positive results from a Phase 2a study evaluating the safety and efficacy o
Read more →SNYSanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate High seroconversion across the three dosages tested and comparable tolerability to other unmodified mRNA COVID-19 vacci
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine PARIS September 28, 2021 Positive interim results from a Phase 1/2 study1 of Sanofi s mRNA-based COVID-19 vaccine candidate confirm the potential of recently-acquired Translate Bio s mess
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) New Dupixent (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV More than 30 present
New Dupixent (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV PARIS and TARRYTOWN, N.Y. September 21, 2021 - New Dupixent (dupilumab) analyses in patients as young as 6 years old with moderate-to-se
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics PARIS
Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics PARIS September 14, 2021 - Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company s efforts to develop trans
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus PARIS
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus PARIS September 9, 2021 The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA approves Nexviazyme (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease * Approval is based on positive Phase 3 data
FDA approves Nexviazyme (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease PARIS August 6, 2021 - The U.S. Food and Drug Administration (FDA) has approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients one year of
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development * Accelerates development of current Sanofi
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development PARIS and LEXINGTON, Mass August 3, 2021 As part of Sanofi s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines,
Read more →SNYTable of Contents HALF-YEAR MANAGEMENT REPORT (Operating and Financial Review and Prospects) 1 A/ Significant events of the first half of 2021 1 B/ Events subsequent to
HALF-YEAR MANAGEMENT REPORT (Operating and Financial Review and Prospects) 1 A/ Significant events of the first half of 2021 1 B/ Events subsequent to June 30, 2021 4 C/ Consolidated financial statements for the first half of 2021 5 D/ Risk factors and related party t
Read more →SNYTable of Contents 2 HALF-YEAR MANAGEMENT REPORT 40 A Significant events of the first half of 2021 40 B Events subsequent to
2 HALF-YEAR MANAGEMENT REPORT 40 A Significant events of the first half of 2021 40 B Events subsequent to June 30, 2021 43 C Consolidated financial statements for the first half of 2021 44 D Risk factors and related party transactions 62 E Outlook 63 F Appendix - Rese
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Online availability of Sanofi s half-year financial report for 2021 PARIS
Online availability of Sanofi s half-year financial report for 2021 PARIS - July 29, 2021 - Sanofi announces that its half-year financial report for the period ending June 30, 2021 is now available and has been filed with the French market regulator Autorit des march s financie
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris PARIS - 07/13/2021 - Tony Estanguet, Chairman of Paris 2024, Paul H
Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic PARIS - 07/13/2021 - Tony Estanguet, Chairman of Paris 2024, Paul Hudson, Sanofi Chief Executive Officer, and Serge Weinberg, Chairman of Sanofi s Board of Directors, today announced Sanofi will beco
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi launches dedicated vaccines mRNA Center of Excellence * Approximately 400million investment annually to accelerate end-to-end R&D of next-generation vacci
Sanofi launches dedicated vaccines mRNA Center of Excellence 2021 - Sanofi will invest approximately 400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by br
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) European Commission approves Aubagio (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remi
European Commission approves Aubagio (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis PARIS June 18, 2021 - The European Commission (EC) has approved Aubagio (teriflunomide) for
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for he
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia PARIS June 11, 202
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi launches its new global employee share ownership plan PARIS
Sanofi launches its new global employee share ownership plan PARIS - June 7, 2021 - Sanofi today launches Action 2021, its global employee share ownership plan, open to 92,000 employees in 73 countries. The program, similar to programs carried out since 2013, clearly demonstrat
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi provides update on venglustat clinical program PARIS JUNE 1, 2021 A pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease
Sanofi provides update on venglustat clinical program PARIS JUNE 1, 2021 A pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease (ADPKD) did not meet futility criteria, and the company has halted the clinical program in ADPKD. The safety profile
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting * Early clinical data for investigational oral selective estrogen receptor
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting PARIS May 19, 2021 New research being presented at the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8 highlights Sanofi s transformative science an
Read more →SNYQ1 2021 sales increase driven by growth drivers Dupixent and Vaccines Specialty Care sales grew due to strong Dupixent performance ( 1,047 million) and oncology launches Vaccines up driven by PPH franchise and demand for
Q1 2021 sales increase driven by growth drivers Dupixent and Progress on implementation of the Corporate Social Responsibility Q1 2021 Change Change at CER IFRS net sales reported 8,591m -4.3 % +2.4 % IFRS net income reported 1,566m -7.0 % IFRS EPS report
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research * Projects led by collaborating researchers from the two org
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology PARIS and Palo Alto, CA May 6, 2021 Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scie
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Annual General Meeting of
Annual General Meeting of April 30, 2021 Paris, France April 30, 2021 The Combined General Shareholders Meeting of Sanofi was held on April 30, 2021, without the physical presence of its shareholders, in accordance with the derogating measures adapting the rules governing the d
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) European Commission approves second indication of Sarclisa (isatuximab) for relapsed multiple myeloma * Approval based on Phase 3 IKEMA study demonstrating Sarcl
European Commission approves second indication of Sarclisa (isatuximab) for relapsed multiple myeloma PARIS April 19, 2021 Today, the European Commission (EC) approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patien
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities * Sanofi will invest 400 million o
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities PARIS April 12, 2021 - Sanofi today announced a 400 million investment over five years to create a unique vaccine production center in Singapore, push
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA approves Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma * Sarclisa regimen
FDA approves Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma PARIS March 31, 2021- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with carfilzomib an
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Phase 3 trial of Libtayo (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival * Libtayo is the first immuno
Phase 3 trial of Libtayo (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival PARIS and TARRYTOWN, N.Y. March 15, 2021 Positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating Sano
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Filing of the 2020 U.S. Form 20-F and French Document d Enregistrement Universel containing the Annual Financial Report
Filing of the 2020 U.S. Form 20-F and French Document d Enregistrement Universel containing the Annual Financial Report PARIS, France March 4, 2021 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its Document d En
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA approves Libtayo (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of 50% * Libtayo was su
FDA approves Libtayo (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of 50% PARIS and TARRYTOWN, N.Y. February 22, 2021 - The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo (c
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) The Lancet publishes Libtayo (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expre
The Lancet publishes Libtayo (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of 50% PARIS and TARRYTOWN, N.Y. February 12, 2021 The Lancet today published results from a pivotal trial des
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA approves Libtayo (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma * Following Priority Review Libtayo recei
FDA approves Libtayo (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma PARIS and TARRYTOWN, N.Y. February 9, 2021 - The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the fi
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer * The new c
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer PARIS - January 12th, 2021 - Sanofi chooses EUROAPI as the name for the future leading European company dedicated to the develop
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L * Continues to build on Sanofi s
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator CAMBRIDGE, UK January 11, 2021 Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immu
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030 * A new five-year US$ 25 million (US$ 5 m
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030 PARIS - December 15, 2020 - Sanofi has signed on December 10th a renewed partnership agreement with the World Health Organization (WHO), consolidating a 20-y
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly Phase 1/2 interi
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly PARIS and LONDON December 11, 2020 Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine pr
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Dupixent (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis Pivotal tr
Dupixent (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis PARIS and TARRYTOWN, N.Y. November 30, 2020 The European Commission (EC) has extended the marketing authorization for Dupixent
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) European Commission approves MenQuadfi , the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older EC approval base
European Commission approves MenQuadfi , the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older PARIS November 23 The European Commission (EC) has approved MenQuadfi for active immunization of individuals from the age of 12 mont
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) European Commission approves Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older * First and
European Commission approves Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older PARIS November 18, 2020 The European Commission has granted a marketing authorization for Supemtek , a quadrivalent (four-strain)
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products * Adds proprietary next generation natural killer (K-NK) c
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products November 2, 2020 Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative off the shelf natural killer (NK) cell based medicines for the treatment of
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent (alirocumab) * Ruling invalidates Amgen s European patent claims directed to PC
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent (alirocumab) PARIS October 29, 2020 The European Patent Office (EPO) Technical Boards of Appeal has today ruled in Sanofi and Regeneron s favor, invalidating certain claims of Amgen s European pat
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Dupixent (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at sc
(dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings PARIS and TARRYTOWN, N.Y. October 26, 2020 Additional positive results were announced from Part A of a pivot
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies * mRNA-based vaccine candidate MRT5500 induced poten
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical PARIS and LEXINGTON, MASS. October 15, 2020 Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA)
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease Avalglucosidase alfa,
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy PARIS October 2, 2020 The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for avalglucosidase alfa, fo
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi completes Principia Biopharma Inc. acquisition * Principia Biopharma Inc. is now a wholly owned subsidiary of Sanofi PARIS
Sanofi completes Principia Biopharma Inc. acquisition PARIS September 28, 2020 Sanofi announced today the successful completion of its acquisition of Principia Biopharma Inc. ( Principia ) for $100 per share in cash. The Principia acquisition further strengthens our core areas
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine * Agreements relate to vaccine candi
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine PARIS and LONDON September 22, 2020 Sanofi and GSK have today signed agreements with the Government of Canada for the supply of up to 72 million doses o
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA grants Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis * Designation based on positive results from Part A of pivotal Phas
Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis PARIS and TARRYTOWN, N.Y., September 14, 2020 The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Dupixent (dupilumab) for the treatment of patients 12 yea
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate * Pre-clinical studies show promising safety
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate PARIS and LONDON Sept. 3, 2020 Sanofi and GSK today started the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to acquire Principia Biopharma * Further strengthens core R&D areas of autoimmune and allergic diseases * Provides full control of brain-penetrant BTK inh
Sanofi to acquire Principia Biopharma PARIS and SOUTH SAN FRANCISCO, Calif. August 17, 2020 Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreem
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine * Discussions relate to vaccine candidate using
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine PARIS and LONDON July 31, 2020 Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Online availability of Sanofi s half-year financial report for 2020 PARIS (France)
Online availability of Sanofi s half-year financial report for 2020 PARIS (France) July 29, 2020 Sanofi announces that its half-year financial report for the period ending June 30, 2020 is now available and has been filed with the French market regulator Autorit des march s fin
Read more →SNYDocument 2. HALF-YEAR MANAGEMENT REPORT A SIGNIFICANT EVENTS OF THE FIRST HALF OF 2020 A.1. FIRST-HALF OVERVIEW In the first half of 2020, and since the onset of the pandemic, Sanofi has played a leading role in the figh
A SIGNIFICANT EVENTS OF THE FIRST HALF OF 2020 A.1. FIRST-HALF OVERVIEW In the first half of 2020, and since the onset of the pandemic, Sanofi has played a leading role in the fight against COVID-19 on multiple fronts On February 18, 2020, Sanofi announced that it would leverag
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients PARIS and TARRYTOWN, N.Y.
Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients PARIS and TARRYTOWN, N.Y. - July 2, 2020 Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara (sarilumab) 400 mg in CO
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patien
Sanofi s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients PARIS June 23, 2020 Sanofi Chief Executive Officer Paul Hudson, Global Head of R&D John Reed, M.D., Ph.D., and me
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease Avalglucosidas
Sanofi s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease PARIS June 16, 2020 Sanofi s investigational enzyme replacement therapy (ERT), avalglucosidase alfa, showed clinically meaningful
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to present growth opportunities and development strategy for Dupixent (dupilumab) in type 2 inflammatory diseases Additional data contribute to the growin
Sanofi to present growth opportunities and development strategy for Dupixent (dupilumab) in type 2 inflammatory diseases Sanofi commercial and R&D executives will provide an overview of the growth and development strategy for Dupixent (dupilumab) in the third of its five-part
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to launch Action 2020 , a worldwide employee stock purchase plan * A plan taking place in almost 75 countries * Subscription per five shares entitle the e
Sanofi to launch Action 2020 , a worldwide employee stock purchase plan PARIS June 3, 2020 Sanofi announces the launch of Action 2020 on June 8, 2020, a worldwide stock purchase plan reserved for its employees, which should take place in almost 75 countries. Sanofi s strategy a
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi announces pricing of Regeneron stock offering Sanofi announces sale of 21.6 million shares held in Regeneron Gross proceeds of $11.1 billion to Sanofi to
Sanofi announces pricing of Regeneron stock offering PARIS May 26, 2020 Sanofi today announced that it has agreed to sell 11.8 million shares of Regeneron, Inc. (NASDAQ: REGN) common stock through a registered offering at a price of $515.00 per share. As previously announced, R
Read more →SNYResponse to COVID-19 global health crisis Sanofi showed resilience and maintained full business continuity worldwide including its global industrial network. Separate collaborations announced with BARDA, Translate Bio an
Response to COVID-19 global health crisis Q1 2020 sales growth performance driven by Dupixent R&D advances and regulatory milestones Q1 2020 Change Change at CER IFRS net sales reported 8,973m +6.9% +6.6% IFRS net income reported 1,683m +48.0% - IFRS EPS reported 1.
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease * Sutimlimab targets C1-
FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold PARIS May 14, 2020 The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi s Biologics License Application (BLA) for sutimlimab for th
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Libtayo (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma * Objective responses seen in 29% of patients
Libtayo (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma Paris and Tarrytown, NY May 5, 2020 - Topline data for a pivotal, single-arm, open-label trial for Sanofi and Regeneron s PD-1 inhibitor Libtayo (cemiplimab) in
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis * Sanofi to host virtual scientific session April
Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis PARIS April 17, 2020 Sanofi will host a scientific session to present detailed data from their Phase 2b trial evaluating its investigational BTK (Bruton s tyrosine ki
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 * Companies to combine innovative technologies to develop an adjuvanted CO
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 PARIS and LONDON April 14, 2020 - Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both c
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi finalizes Praluent (alirocumab) restructuring with Regeneron Paris
Sanofi finalizes Praluent (alirocumab) restructuring with Paris April 6, 2020 Sanofi has finalized the planned restructuring related to Praluent (alirocumab) with Regeneron Pharmaceuticals, Inc. Effective April 1, 2020, Sanofi will have sole responsibility for Praluent outside
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Information on Sanofi s Shareholder s General Meeting of Tuesday
Information on Sanofi s Shareholders General Meeting of Tuesday, April 28, 2020 Paris (France) April 1st, 2020 - In view of the current Covid-19 (coronavirus) pandemic in France and around the world, Sanofi s Board of Directors has decided to hold its Annual General Meeting con
Read more →SNYFirst patient outside U.S. treated in global Kevzara (sarilumab) clinical trial program for patients with severe COVID-19 * Phase 2/3 trial initiated in Italy, Spain, Germany, France, Canada, and Russia and
First patient outside U.S. treated in global Kevzara (sarilumab) clinical trial program for patients with severe COVID-19 PARIS and TARRYTOWN, N.Y. March 30, 2020 The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara (sa
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Filing of the 2019 U.S. Form 20-F and French Document d Enregistrement Universel containing the Annual Financial Report
Filing of the 2019 U.S. Form 20-F and French Document d Enregistrement Universel containing the Annual Financial Report PARIS, France March 5, 2020 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its Document d En
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*) * New major API company 1 would secure significant API
Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*) Paris - February 24, 2020 Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingre
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA accepts for priority review Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis * If approved, Dupixent would be t
FDA accepts for priority review Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis PARIS and TARRYTOWN, NY January 28, 2020 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics Lic
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi Completes Acquisition of Synthorx, Inc. * Synthorx, Inc. is now a fully owned subsidiary of Sanofi PARIS (FRANCE)
Sanofi Completes Acquisition of Synthorx, Inc. PARIS (FRANCE) January 23, 2020 Sanofi announced today the successful completion of its acquisition of Synthorx, Inc. ( Synthorx ) for $68 per share in cash. The acquisition of Synthorx perfectly aligns with our R&D strategy, enh
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara (sarilumab) and Praluent (alirocumab) PARIS (FRANCE)
Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara (sarilumab) and Praluent (alirocumab) PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced their intent to simplify t
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion Proprietary immuno-oncology (IO) platform synergistic with Sanofi s existing th
Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion PARIS and San Diego, California December 9, 2019 Sanofi and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people sufferin
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation PARIS
Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation PARIS - October 31, 2019: - Sanofi announced today that it has entered into an agreement to settle (the "Settlement Agreement") the previously disclosed action UMB Bank, N.A., as Trustee
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing * One of the first digital manufa
Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech PARIS October 15, 2019 Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world s f
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) U.S. District Court invalidates Amgen patent claims targeting PCSK9 * Court rules in favor of Sanofi and Regeneron in ongoing Praluent (alirocumab) patent litiga
U.S. District Court invalidates Amgen patent claims targeting PCSK9 PARIS and TARRYTOWN, NY August 28, 2019 Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law tha
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Dupixent (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis * U.S. FDA submission for chil
Dupixent (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis PARIS and TARRYTOWN, NY August 6, 2019 A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat severe atopic dermatitis in children aged 6
Read more →SNYHALF-YEAR FINANCIAL REPORT Table of Contents 1- CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 1 CONSOLIDATED BALANCE SHEETS ASSETS 1 CONSOLIDATED BALANCE SHEETS SHAREHOLDERS EQUITY AND LIABILITIES 2 CONSOLIDATED
1- CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 1 CONSOLIDATED BALANCE SHEETS ASSETS 1 CONSOLIDATED BALANCE SHEETS SHAREHOLDERS EQUITY AND LIABILITIES 2 CONSOLIDATED INCOME STATEMENTS 3 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 4 CONSOLIDATED STATEME
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care PARIS
Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care PARIS July 23, 2019 Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the US. Under
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma PARIS
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma PARIS July 10, 2019 - The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapse
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and Google to develop new healthcare Innovation Lab PARIS
Sanofi and Google to develop new healthcare Innovation Lab PARIS June 18, 2019 Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging dat
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Communication from the Board of Directors Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer PARIS
Communication from the Board of Directors Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer PARIS June 7, 2019 At its meeting on June 6th of 2019, Sanofi s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succ
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple m
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma Paris June 2, 2019 Pivotal Phase 3 ICARIA-MM trial results demonstrated that isatuximab added to pomalidomide
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA approves Praluent (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization Praluent is the first PCSK9 inhibitor that has s
FDA approves Praluent (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization PARIS and TARRYTOWN, NY April 26, 2019 The U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, an
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease Approval is
Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease PARIS and TARRYTOWN, NY March 15, 2019 The European Commission (EC) has approved a new indication for Praluent (alirocumab), to
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies * Praluent (alirocumab) continu
Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 PARIS and TARRYTOWN, NY February 25, 2019 - Sanofi and Regeneron Pharmaceuticals Inc. announced they strongly disagree with certain aspects of today s jury ver
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) CHMP recommends approval of Praluent (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease PARIS and TARRY
CHMP recommends approval of Praluent (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease PARIS and TARRYTOWN, NY February 4, 2019 The European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs * Companies select two clinical-stage bispecific antibodies
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs PARIS and TARRYTOWN, NY January 7, 2019 Sanofi (EURONEXT: SAN, NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have restructured their global Immuno-oncology Di
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq PARIS, FRANCE
Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq PARIS, FRANCE December 18, 2018 - Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq)
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) ODYSSEY OUTCOMES investigators highlight at AHA that Praluent (alirocumab) was associated with fewer deaths from any cause * Mortality risk reduction greater in pa
ODYSSEY OUTCOMES investigators highlight at AHA that Praluent (alirocumab) was associated with fewer deaths from any cause PARIS and Tarrytown, N.Y. November 11, 2018 New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart A
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA grants priority review for Dupixent (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis Paris and Tarryto
FDA grants priority review for Dupixent (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis Paris and Tarrytown, NY November 6, 2018 The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemen
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA approves asthma indication for Dupixent (dupilumab) * Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype * Only bi
FDA approves asthma indication for Dupixent (dupilumab) PARIS and TARRYTOWN, NY October 19 2018 - The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi completes divestiture of Zentiva to Advent Paris
Sanofi completes divestiture of Zentiva to Advent Paris October 1, 2018 Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule fo
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to refocus two global business units Appoints Dieter Weinand to lead new Primary Care business unit New China & Emerging Markets business to be led by Olivi
Sanofi to refocus two global business units Paris September 13, 2018 - Sanofi will change the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations in mature markets and across emerging markets.1 will create a new Primary
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi reaches civil settlement with US SEC Paris
Sanofi reaches civil settlement with US SEC Paris September 4, 2018 Sanofi has reached a civil settlement with the U.S. Securities and Exchange Commission (SEC) fully resolving the SEC s investigation into possible violations of the U.S. Foreign Corrupt Practices Act. The sett
Read more →SNYCONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS CONTENTS 1 CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 1 CONSOLIDATED BALANCE SHEETS ASSETS 1 CONSOLIDATED BALANCE SHEETS EQUITY AND LIABILITIES 2 CONSOLIDA
CONSOLIDATED FINANCIAL STATEMENTS 1 CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 1 CONSOLIDATED BALANCE SHEETS ASSETS 1 CONSOLIDATED BALANCE SHEETS EQUITY AND LIABILITIES 2 CONSOLIDATED INCOME STATEMENTS 3 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 4
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1 st Paris
Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st Paris July 26, 2018 Roberto Pucci, Head of Human Resources, will retire from Sanofi after more than 9 years of service with the company. He will be succeeded in the
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) CHMP recommends approval of Cablivi (caplacizumab) * First therapeutic to receive positive CHMP opinion for treatment of a rare blood disorder called acquired thro
CHMP recommends approval of Cablivi (caplacizumab) Paris, France - June 29, 2018 - The European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe for the treatment of adults experiencing an epis
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer Paris
Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer Paris June 19, 2018 - Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Commit
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi successfully prices USD 2 billion bond issue Paris, France
Sanofi successfully prices USD 2 billion bond issue Paris, France - June 13, 2018 - Sanofi has successfully priced its offering of USD 2 billion of notes denominated in US dollars, across 2 tranches: The offer was made pursuant to Sanofi s shelf registration statement filed wit
Read more →SNYINFORMATION ON Q1 2018 FINANCIAL RESULTS Q1 2018 Change Change at Constant Exchange Rates Net sales reported 7,898m -8.7 % -0.4 % Net income reported 1,016m -82.2 % ( 1 ) Earnings per Share reported 0.81 -82.0 % ( 2 ) Bu
INFORMATION ON Q1 2018 FINANCIAL RESULTS Q1 2018 Change Change at Constant Exchange Rates Net sales reported 7,898m -8.7 % -0.4 % Net income reported 1,016m -82.2 % ( 1 ) Earnings per Share reported 0.81 -82.0 % ( 2 ) Business net income ( 3 ) 1
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Launches Action 2018 , a Worldwide Employee Stock Purchase Plan A plan taking place in almost 80 countries Subscription per five shares entitle the employee
Sanofi Launches Action 2018 , a Worldwide Employee Stock Purchase Plan Paris, France June 11, 2018 Sanofi launches today Action 2018 , a worldwide stock purchase plan reserved for its employees. In doing such a capital increase, Sanofi intends to better associate its employees
Read more →SNYInformation on Q1 2018 Financial Results Q1 2018 Change Change at Constant Exchange Rates Net sales reported 7,898m -8.7 % -0.4 % Net income reported 1,016m -82.2 % ( 1 ) Earnings per Share reported 0.81 -82.0 % ( 2 ) Bu
Information on Q1 2018 Financial Results Q1 2018 Change Change at Constant Exchange Rates Net sales reported 7,898m -8.7 % -0.4 % Net income reported 1,016m -82.2 % ( 1 ) Earnings per Share reported 0.81 -82.0 % ( 2 ) Business net income ( 3 ) 1
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent (dupilumab) improved moderate-to-severe asthma Results showed Dupixent demon
New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent (dupilumab) improved moderate-to-severe asthma Paris and Tarrytown, NY May 21, 2018 The New England Journal of Medicine (NEJM) today published detailed results from two Phase 3 trials for the
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Annual General Shareholders Meeting of
Annual General Shareholders Meeting of May 2, 2018 Paris (France) May 2, 2018 - The Combined General Shareholders Meeting of Sanofi was held today at the Palais des Congr s in Paris under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 Paris 24 th April 2018 Elias Zerhouni, M.D., Head of Global Rese
Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 Paris 24th April 2018 Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service w
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to invest 350 million in Canadian vaccine facility Expansion demonstrates company s commitment to innovation and leadership in global public health New Toro
Sanofi to invest 350 million in Canadian vaccine facility April 12, 2018 Sanofi is investing 350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investm
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma Paris and Tarrytown, NY
EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma Paris and Tarrytown, NY April 3, 2018 The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cemiplimab for the treatment of p
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review sotagliflozin as potential treatment for type 1 diabetes Paris
EMA to review sotagliflozin as potential treatment for type 1 diabetes Paris March 29, 2018 The European Medicines Agency (EMA) has accepted for review Sanofi s regulatory submission for sotagliflozin. If approved, the oral treatment would be used as an addition to insulin ther
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi successfully prices EUR 8 billion of bond issues Paris, France
Sanofi successfully prices EUR 8 billion of bond issues Paris, France March 15, 2018 - Sanofi has successfully priced its offering of EUR 8 billion of notes (the Notes ) across 6 tranches: issues are made under the company s Euro Medium Term Note Programme. The transaction en
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron announce plans to make Praluent more accessible and affordable for patients with the greatest health risk and unmet need Precision medicine ap
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron announce plans to make Praluent more accessible and affordable for patients with the greatest health risk and unmet need Paris, France and Tarrytown, NY March 10, 2018 To help ensure more aff
Read more →SNYSanofi Completes Acquisition of Bioverativ Inc. Bioverativ Inc. is a fully owned subsidiary of Sanofi Paris (France)
Sanofi Completes Acquisition of Bioverativ Inc. Bioverativ Inc. is a fully owned subsidiary of Sanofi Paris (France) March 8, 2018 Sanofi announced today the successful completion of its acquisition of Bioverativ Inc. ( Bioverativ ) for $105 per share in cash. The addition of
Read more →SNYSources: Sanofi (EURONEXT: SAN) (NYSE: SNY) Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform Evotec-led platform open to academia, biotechnology a
Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform Hamburg, Germany and Paris, France March 2018 - Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and d
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director * Creates new Scientific Committee and nominates Thomas S dhof as C
Sanofi s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director PARIS, France March 6, 2018 - At its meeting held on March 6, 2018, Sanofi s Board of Directors proposed to submit the appointment of Emmanuel Babeau as new independent director, as
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA to review Dupixent (dupilumab) as potential treatment for moderate-to-severe asthma Paris and Tarrytown, NY
FDA to review Dupixent (dupilumab) as potential treatment for moderate-to-severe asthma Paris and Tarrytown, NY March 2, 2018 The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of Dupixent (dupilumab) as an add-on
Read more →SNYSanofi to acquire Ablynx for 3.9 Billion Strengthens Sanofi s R&D strategy with innovative Nanobody technology platform Expands growing rare blood disorders franchise with Ablynx s late-stage investigational caplacizumab
Sanofi to acquire Ablynx for 3.9 Billion Paris, France and Ghent, Belgium January 29, 2018 Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies , entered into a definitive agreement under which Sanofi will offer to acquire all o
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to Acquire Bioverativ for $11.6 Billion * Expands Sanofi s presence in specialty care and strengthens leadership in rare diseases * Adds leader in the growi
Sanofi to Acquire Bioverativ for $11.6 Billion (France) and Waltham, Mass. January 22, 2018 Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which Sanofi wi
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee Paris, France
Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Paris, France - January 19, 2018 - Sanofi has appointed Dominique Carouge as Executive Vice President Head of Business Transformation, effective February 15, 2018. In th
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs * Companies also announce submission of dupilumab supple
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs and Tarrytown, N.Y. January 8, 2018 Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will accelerate and expand investment for the clinical development of the PD-
Read more →SNYSanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis * Patisiran Marketing Authorization Application to be reviewed
Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis Cambridge, Mass. December 18, 2017 - Sanofi Genzyme, the specialty care global business unit of Sanofi, and Alnylam Pha
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi presents R&D strategy and innovative pipeline Robust pipeline expected to support long-term growth 9 planned regulatory submissions over next 18 months At l
Sanofi presents R&D strategy and innovative pipeline PARIS, FRANCE - 13 December 2017 Sanofi will host an analyst meeting in Paris today to discuss the company s Research and Development strategy, development pipeline and milestones for 2018. The company will highlight the prog
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi s Toujeo met main objective in head-to-head study versus insulin degludec First head-to-head randomized clinical trial comparing the efficacy and safety of
Sanofi s Toujeo met main objective in head-to-head study versus insulin degludec PARIS, FRANCE December 4, 2017 Sanofi s Toujeo met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, comparing Toujeo with insulin degludec. Sanofi
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi, Principia agree to develop multiple sclerosis drug candidate * Clinical-stage oral drug candidate (PRN2246) with the potential to treat multiple sclerosis
Sanofi, Principia agree to develop multiple sclerosis drug candidate with the potential to treat multiple sclerosis future milestone payments could total Paris, France and South San Francisco, Calif November 9, 2017 Sanofi will develop Principia Biopharma Inc. s experimental
Read more →SNYSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma * First s
Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma Paris, France and Tarrytown, NY October 31, 2017 Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase
Read more →SNYSanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus and Lantus SoloStar Paris, France
Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus and Lantus SoloStar Paris, France October 24, 2017 Sanofi (EURONEXT: SAN and NYSE: SNY) today filed a patent infringement suit against Mylan N.V., Mylan GmbH, Mylan Inc., and Mylan Pharmaceuticals Inc. (collect
Read more →SNYSanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to- Severe Eosinophilic Esophagitis - Late-breaking oral abstract presented at the World Congress
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to- Severe Eosinophilic Esophagitis Late-breaking oral abstract presented at the World Congress of Gastroenterology - Paris, France and Tarrytown, N.Y. October 16, 2017
Read more →SNYAppellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent (alirocumab) Praluent continues to be available to patients in the U.S. Paris, France and Tarryt
Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent (alirocumab) Praluent continues to be available to patients in the U.S. Paris, France and Tarrytown, N.Y., October 5, 2017 Sanofi and Regeneron Pharmaceuticals, Inc.
Read more →SNYSanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular and Member of the Executive Committee Paris, France
Sanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular and Member of the Executive Committee Paris, France - October 2, 2017 - Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effective immediately. In
Read more →SNYSanofi and Regeneron Announce Positive Study Results for Dupixent (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis Late-breaking oral abstract of Phase 3 CAFÉ study presented at the
Sanofi and Regeneron Announce Positive Study Results for Dupixent (dupilumab) in Patients With Moderate-to-Severe Late-breaking oral abstract of Phase 3 CAF study presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress Paris, France and Tarrytown
Read more →SNYSanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma Paris, France and Tarrytown, New York
Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma Paris, France and Tarrytown, New York September 8, 2017 Sanofi and Regeneron Pharmaceuticals, Inc. today announced that th
Read more →SNYSanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus Paris, France
Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus Paris, France August 8, 2017 - Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. ( Merck ) on August 8, 2017 in the United States District Court for the District
Read more →SNYH ALF -Y EAR F INANCIAL R EPORT CONTENTS 1 CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS
HALF-YEAR FINANCIAL REPORT 1 CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 CONSOL
Read more →SNYSanofi and Regeneron Receive Positive CHMP Opinion for Dupixent (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - First investigational targeted biologic in the European Union
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - First investigational targeted biologic in the European Union to receive positive CHMP opinion for atopic dermatitis - Paris, Franc
Read more →SNYSanofi and Regeneron Announce Approval of Kevzara (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union Paris, France and Tarrytown, N.Y.
Sanofi and Regeneron Announce Approval of Kevzara (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union Paris, France and Tarrytown, N.Y. June 27, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. announced today that
Read more →SNYSanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia - Data presented at the 77 th Scientific Se
Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia presented at the 77th Scientific Sessions of the American Diabetes Paris, France and Tarrytown, N.Y., June 11, 201
Read more →SNYSanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar - Positive opinion based on a clinical development program involving over 1,000 people with type 1 or type 2 diabetes - Paris, France
Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar - Positive opinion based on a clinical development program involving over 1,000 people with type 1 or type 2 diabetes - Paris, France May 19, 2017 - Sanofi announced today that the Committee for Med
Read more →SNYInformation on Q1 2017 Financial Results Q1 2017 Change Change at CER IFRS net sales reported 8,648m +11.1 % +8.6 % IFRS net income reported 5,701m +424.5 % IFRS EPS reported 4.52 +438.1 % Business net income (1) 1,795m
Information on Q1 2017 Financial Results Q1 2017 Change Change at CER IFRS net sales reported 8,648m +11.1 % +8.6 % IFRS net income reported 5,701m +424.5 % IFRS EPS reported 4.52 +438.1 % Business net income (1) 1,795m +4.2 % +1.0 % First
Read more →SNYAnnual General Shareholders Meeting of
Annual General Shareholders Meeting of May 10, 2017 - Shareholders approval of the financial statements for 2016 - Dividend of 2.96 per share payable as of May 18, 2017 - Board Composition: renewal and appointments - Paris, France - May 10, 2017 - The Combined General Shareho
Read more →SNYSanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee Paris, France
Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee Paris, France April 5, 2017 Sanofi today announced the appointment of Bill Sibold as Executive Vice President Sanofi Genzyme, effective July 1, 2017. In this role, Mr. Si
Read more →SNYSanofi and Regeneron Announce FDA Approval of Dupixent (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis - Dupixent will be available later this week to U
Sanofi and Regeneron Announce FDA Approval of (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis - Dupixent will be available later this week to U.S. patients suffering from this chronic and debilitating form of eczema - Pari
Read more →SNYSanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility - The large-scale facility, to be built in Visp, Switzerland, will be established through a joint
Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility - The large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture with an initial investment of around CHF 290 million ( 270 mill
Read more →SNYAppeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process - Praluent continues to be available to patients in the U.S. - Paris, France and Tarrytown, New York
Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process - Praluent continues to be available to patients in the U.S. - Paris, France and Tarrytown, New York February 8, 2017 Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) and Sanofi a
Read more →SNYSanofi s Xyzal Allergy 24HR Approved for Over-the-Counter Use in the United States Paris, France
Sanofi s Xyzal Allergy 24HR Approved for Over-the-Counter Use in the United States France February 1, 2017 Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Xyzal Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms assoc
Read more →SNYSuliqua TM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes Paris, France
SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes Paris, France - January 17, 2017 - Sanofi announced today that the European Commission has granted marketing authorization in Europe for SuliquaTM, the once-daily titratable fixed-ratio c
Read more →SNYSanofi Announces Soliqua 100/33 Now Available in the U.S. Paris, France
Sanofi Announces Soliqua 100/33 Now Available in the U.S. Paris, France January 4, 2017 Sanofi announced today that Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicate
Read more →SNYSanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017 - Both companies will become global leaders in two different sectors of the pharmaceutical market - Paris (France) and Ingelheim (Germa
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017 - Both companies will become global leaders in two different sectors of the pharmaceutical market - Paris (France) and Ingelheim (Germany) 2nd January 2017 Sanofi and Boehringer Ingelheim con
Read more →SNYSanofi Receives FDA Approval of Soliqua 100/33, for the Treatment of Adults with Type 2 Diabetes - First Injectable Once-Daily Combination of Basal Insulin and GLP-1 Receptor Agonist Approved in U.S. - Pari
Sanofi Receives FDA Approval of Soliqua 100/33, for the Treatment of Adults with Type 2 Diabetes - First Injectable Once-Daily Combination of Basal Insulin and GLP-1 Receptor Agonist Approved in Paris, France November 21, 2016 Sanofi announced today that the U.S. Food and Drug
Read more →SNYSanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis Paris and Tarrytown, N.Y.
Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis Tarrytown, N.Y. October 28, 2016 Sanofi and Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) issued a
Read more →SNYSanofi and Regeneron Announce Positive Dupixent (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine - Data to be presented today during a late breaking abstract sessi
Sanofi and Regeneron Announce Positive Dupixent (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress
Read more →SNYSanofi and Verily Life Sciences Announce Launch of Onduo, a Joint Venture to Develop Comprehensive Diabetes Management Platform - Joshua Riff, M.D Named Chief Executive Officer - Collaboration established w
Sanofi and Verily Life Sciences Announce Launch of Onduo, a Joint Venture to Develop Comprehensive Diabetes Management Platform - Joshua Riff, M.D Named Chief Executive Officer - Collaboration established with regional healthcare providers Allegheny Health and Sutter Health Ne
Read more →SNYSanofi successfully prices EUR 3 billion bond issue Paris, France
Sanofi successfully prices EUR 3 billion bond issue Paris, France - September 6, 2016 - Sanofi announces that it has successfully priced its offering of EUR 3 billion of notes across 3 tranches: drawn under the Company s Euro Medium Term Note Programme. The transaction enables
Read more →SNYSanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Paris, France
Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Paris, France August 19, 2016 - Sanofi announced today that it has submitted updated information on the pen delivery device as part of th
Read more →SNYSanofi Enters into Confidentiality Agreement with Medivation and Will be Provided Due Diligence Access and Confidential Information - Sanofi Agrees to Standstill and to Withdraw Consent Solicitation- Paris,
Sanofi Enters into Confidentiality Agreement with Medivation and Will be Provided Due Diligence Access and Confidential Information - Sanofi Agrees to Standstill and to Withdraw Consent Solicitation- Paris, France July 5, 2016 Sanofi has confirmed that it has entered into a co
Read more →SNYStatus of CVR Product Sales Milestone #1 as of
Status of CVR Product Sales Milestone #1 as of June 30, 2016 Capitalized terms in this document other than proper nouns have the meaning ascribed to them in the Contingent Value Rights Agreement by and between Sanofi-Aventis and American Stock Transfer & Trust Company, LLC date
Read more →SNYSanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic
Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients These data, along with previous Phase 3 studies, wil
Read more →SNYSanofi Announces Expiration of Hart-Scott-Rodino Waiting Period Regarding Proposed Acquisition of Medivation Paris, France
Sanofi Announces Expiration of Hart-Scott-Rodino Waiting Period Regarding Proposed Acquisition of Medivation Paris, France June 14, 2016 - Sanofi today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connec
Read more →SNYSanofi Files Definitive Consent Solicitation to Remove and Replace Medivation s Board -Mails Letter to Medivation Shareholders- -Urges Shareholders Vote the WHITE Consent Card- Paris, France
Sanofi Files Definitive Consent Solicitation to Remove and Replace Medivation s Board -Mails Letter to Medivation Shareholders- -Urges Shareholders Vote the WHITE Consent Card- Paris, France June 13, 2016 Sanofi today announced that it has filed definitive consent solicitation
Read more →SNYThis presentation contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward looking statements are statements that are not historical facts. These stateme
Bard, Inc., a developer and manufacturer of medical technologies From 1982 to 1999, held numerous executive positions at Wyeth (formerly American Home Products Corporation) Currently serves on the Board of Directors of Sequenom, Inc. and Quidel Corp. Served as Director of STAAR S
Read more →SNYSanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation s Board of Directors Paris, France
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation s Board of Paris, France June 1, 2016 - Sanofi today announced that it has submitted a written notice to the Secretary of Medivation, Inc. (NASDAQ: MDVN) requesting that the Medivation Board o
Read more →SNYSanofi Files Consent Solicitation To Remove and Replace Medivation s Board Paris, France
Sanofi Files Consent Solicitation To Remove and Replace Medivation s Board Paris, France May 25, 2016 - Sanofi today announced that it has filed preliminary consent solicitation materials with the U.S. Securities and Exchange Commission ( SEC ) seeking to remove and replace eac
Read more →SNYSanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020 Paris, France
Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020 Paris, France May 23, 2016 - Sanofi Chief Executive Officer Olivier Brandicourt, MD, announced today a number of changes to the company s Executive Committee, supporting Sanofi s recently anno
Read more →SNYSanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation - Reiterates Commitment to Consummating Transaction - Paris, France
Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation - Reiterates Commitment to Consummating Transaction - Paris, France - May 12, 2016 - Sanofi today announced that it has filed for premerger notification under the Hart-Scott-Rodino Anti
Read more →SNYSanofi Sends Letter to Medivation's Board of Directors Paris
Sanofi Sends Letter to Medivation's Board of Directors Paris, May 5, 2016 - Sanofi today announced that it has sent a letter to Medivation, Inc.'s (NASDAQ: MDVN) Board of Directors. The full text of the letter reads as follows: 525 Market Street, 36th floor San Francisco, CA 9
Read more →SNYAnnual General Shareholder Meeting of
Annual General Shareholder Meeting of May 4, 2016 Paris, France - May 4, 2016 - The Combined General Shareholder Meeting of Sanofi was held today at the Palais des Congr s in Paris under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by i
Read more →SNYSanofi Comments on Medivation's Rejection of Proposal -Reiterates Commitment to Consummating Transaction- Paris, France
Sanofi Comments on Medivation's Rejection of Proposal -Reiterates Commitment to Consummating Transaction- Paris, France - April 29, 2016 - Sanofi today commented on Medivation, Inc.'s (NASDAQ: MDVN) rejection of Sanofi's non-binding all-cash proposal to acquire Medivation for $
Read more →SNYSanofi Offers to Acquire Medivation for $52.50 Per Share in Cash - Proposal Would Provide Immediate and Certain Value to Medivation's Shareholders - - Combination Would Create Complementary Offerings to Tre
Sanofi Offers to Acquire Medivation for $52.50 Per Share in Cash - Proposal Would Provide Immediate and Certain Value to Medivation's Shareholders - - Combination Would Create Complementary Offerings to Treat Prostate Cancer - - Supports Sanofi's Strategy in Oncology - Paris,
Read more →SNYSanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform - Five-year collaboration encompasses up to 12 targets and prov
Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform - Five-year collaboration encompasses up to 12 targets and provides up to $184 million in milestone payments per target Paris, France
Read more →SNYCAPITALIZATION AND INDEBTEDNESS The following table sets forth our cash and cash equivalents, short term debt, including current portion of long term debt and our capitalization as of
CAPITALIZATION AND INDEBTEDNESS following table sets forth our cash and cash equivalents, short term debt, including current portion of long term debt and our capitalization as of December 31, 2015 (prepared on the basis of International Financial Reporting Standards as issued
Read more →SNYSanofi Pasteur and MSD (Known as Merck in the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies LYON, F
Sanofi Pasteur and MSD (Known as Merck in the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies LYON, France, and KENILWORTH, N.J. - March 8, 2016 - Sanofi Pasteur and MSD,
Read more →SNYFiling of the 2015 U.S. Form 20-F and French Document de R f rence containing the Annual Financial Report Paris, France
Filing of the 2015 U.S. Form 20-F and French Document de R f rence containing the Annual Financial Report Paris, France - March 4, 2016 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its Document de R f rence con
Read more →SNYPRESS RELEASE Paris
Sanofi delivered 2015 business EPS up 8.5% on a reported basis and stable at constant exchange rates consistent with guidance Executing on 2020 strategic roadmap Recent achievements in advancing Sanofi s R&D pipeline of innovative medicines growth in Pharmaceuticals, Vaccines
Read more →SNYSanofi Pasteur s Dengue Vaccine Approved in the Philippines - Dengvaxia s first approval in Asia reaffirms company s vision for priority introduction of the dengue vaccine in endemic countries globally - Ly
Sanofi Pasteur s Dengue Vaccine Approved in the Philippines - Dengvaxia s first approval in Asia reaffirms company s vision for introduction of the dengue vaccine in endemic countries globally - Lyon, France - December 22, 2015 - Sanofi Pasteur, the vaccines division of Sanofi
Read more →SNYSanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap : Sanofi Would Become a Global Leader in Consumer Healthcare and Boehringer Ingelheim Would Become Second largest Animal Health Company Paris
Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap : Sanofi Would Become a Global Leader in Consumer Healthcare and Boehringer Ingelheim Would Become Second largest Animal Health Company Paris and Ingelheim - December 15, 2015 - Sanofi and Boehringer I
Read more →SNYSanofi Sets Out Strategic Roadmap for Long-term Growth Sales CAGR(1) between +3% and +4% at CER over 2015-2020 Six major launches expected to generate aggregate peak sales of 12 bn to 14 bn(2) Business EPS(
Sanofi Sets Out Strategic Roadmap for Long-term Growth Sales CAGR(1) between +3% and +4% at CER over 2015-2020 Six major launches expected to generate aggregate peak sales of 12 bn to 14 bn(2) Business EPS(3) at CER expected to grow faster than sales beginning in 2018 Targeti
Read more →SNYSanofi, Evotec Enter New Research Collaboration to Discover and Develop Novel Diabetes Therapies -Collaboration aims to address critical unmet patient need through next generation diabetes therapies based o
Sanofi, Evotec Enter New Research Collaboration to Discover and Develop Novel Diabetes Therapies -Collaboration aims to address critical unmet patient need through next generation diabetes therapies based on stem cell research - Paris, August 7, 2015 Sanofi announced today th
Read more →SNYHALF-YEAR FINANCIAL REPORT CONTENTS CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLI
HALF-YEAR FINANCIAL REPORT CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 CONSOLIDATED STATEMENTS
Read more →SNYSanofi s New Basal Insulin Lantus XR, Known as Toujeo in the U.S. and Europe, Approved in Japan for the Treatment of Diabetes Mellitus Paris, France
Sanofi s New Basal Insulin Lantus XR, Known as Toujeo in the U.S. and Europe, Approved in Japan for the Treatment of Diabetes Mellitus Paris, France - July 3, 2015 - Sanofi announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing authori
Read more →SNYFDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with Hypercholesterolemia
The FDA Advisory Committee has recommended the approval of Praluent (alirocumab) for patients with hypercholesterolemia, citing its LDL-C lowering benefits outweighing risks. The recommendation was based on positive results from over 5,000 patients in pivotal Phase 3 trials. If approved, Praluent would be the first fully human monoclonal antibody targeting PCSK9 in the U.S.
Read more →SNYSanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis - Includes study in patients who were inadequate responders to, or intolerant
Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis - Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors - - US regulatory submission planned for Q4
Read more →SNYSanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide)
Sanofi announced top-line results from the Phase IIIb ELIXA study, showing that lixisenatide was non-inferior to placebo regarding cardiovascular safety in high-risk type 2 diabetes patients. Full results will be presented at the American Diabetes Association's Scientific Sessions in June 2015. The findings will support a resubmission for U.S. approval later this year.
Read more →SNYShantha will provide up to 37 million doses of Shan5 - Shan5 pentavalent pediatric vaccine will protect children against 5 pediatric diseases - Lyon, France
Shantha will provide up to 37 million doses of Shan5 - Shan5 pentavalent pediatric vaccine will protect children against 5 pediatric diseases - Lyon, France - March 17, 2015 - Sanofi Pasteur, the vaccines division of Sanofi, announced today that its affiliate Shantha Biotechnic
Read more →SNYSanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
Sanofi and Regeneron announced the publication of 18-month results from the ODYSSEY LONG TERM trial for Praluent (alirocumab) in the New England Journal of Medicine. The trial, involving 2,341 high-risk patients, showed a significant reduction in LDL-C levels and fewer cardiovascular events. The findings support Praluent's efficacy and safety when added to statin therapy.
Read more →SNYSanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo Paris, France
Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo Paris, France - February 26, 2015 - Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insul
Read more →SNYSanofi Appoints Olivier Brandicourt as Chief Executive Officer - Tenure as CEO will commence on
Sanofi Appoints Olivier Brandicourt as Chief Executive Officer - Tenure as CEO will commence on April 2, 2015 - Paris - February 19, 2015 - The Board of Directors unanimously appointed Olivier Brandicourt as Chief Executive Officer of Sanofi. Olivier Brandicourt has 28 years o
Read more →SNYEuropean CHMP Adopts Positive Opinion for Genzyme s Cerdelga (eliglustat) Capsules Paris
European CHMP Adopts Positive Opinion for Genzyme s Cerdelga (eliglustat) Capsules Paris - November 21, 2014 - Sanofi and its subsidiary Genzyme announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a p
Read more →SNYSanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis Paris and Tarrytown, New York
Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis Paris and Tarrytown, New York - November 20, 2014 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has
Read more →SNYSanofi nominates Professor Bonnie L. Bassler to its Board of Directors Paris, France
Sanofi nominates Professor Bonnie L. Bassler to its Board of Directors Paris, France - November 18, 2014 - Sanofi today announced the nomination of Bonnie L. Bassler as independent member of its Board of Directors. Professor Bassler, 52, is a Howard Hughes Medical Institute In
Read more →SNYStatement from Sanofi Board of Directors Paris, France
Statement from Sanofi Board of Directors Paris, France Oct 29, 2014 - The Board of Directors held a meeting Wednesday, October 29 at 8am and decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi. As a consequence Christopher A. Viehbacher r
Read more →SNYSanofi Pasteur s Dengue Vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America - Second, large-scale phase III study successfully meets primary endpoint w
Sanofi Pasteur s Dengue Vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America - Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against
Read more →SNYSanofi and Regeneron to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 Paris, France , and Tarrytown, NY
Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 Paris, France, and Tarrytown, NY, August 25, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that d
Read more →SNYSanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin
Sanofi and MannKind have entered a global licensing agreement for Afrezza, a rapid-acting inhaled insulin therapy for diabetes. Sanofi will handle commercialization and regulatory activities, while MannKind will manufacture the product. The agreement includes an upfront payment and milestone payments based on performance. Afrezza is set to launch in the U.S. in early 2015.
Read more →SNYHALF-YEAR FINANCIAL REPORT 2014 CONTENTS CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CO
HALF-YEAR FINANCIAL REPORT CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 CONSOLIDATED STATEMENTS
Read more →SNYFirst Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia
Sanofi Pasteur announced promising results from its phase III dengue vaccine study, showing a 56.5% efficacy against symptomatic dengue in children aged 2 to 14. Notably, the vaccine demonstrated an 88.5% reduction in severe dengue cases and a 67% decrease in hospitalization rates. The safety profile remains favorable, aligning with earlier studies.
Read more →SNYSanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Sanofi and Regeneron announced positive results from a Phase 2b study of dupilumab for moderate-to-severe atopic dermatitis. All doses met the primary endpoint, showing significant improvements in Eczema Area and Severity Index scores. The results support the role of the IL-4/IL-13 pathway in allergic diseases. The companies plan to initiate Phase 3 studies later this year.
Read more →SNYFDA Accepts Sanofi s New Drug Application for Basal Insulin Toujeo Toujeo dossier already accepted by EMA Paris, France
FDA Accepts Sanofi s New Drug Application for Basal Insulin Toujeo Toujeo dossier already accepted by EMA Paris, France July 8, 2014 Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company s New
Read more →SNYSanofi Reports Positive Phase 3 Results for Toujeo(R)
Sanofi announced positive Phase 3 results for Toujeo, showing a significant reduction in low blood sugar events in type 2 diabetes patients compared to Lantus. The pooled analysis from the EDITION trials demonstrated a 31% decrease in nighttime hypoglycemia risk. The results support Toujeo's potential to address unmet needs in diabetes management, with the EMA accepting its marketing authorization dossier.
Read more →SNYSanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR - Both doses of investigational drug sarilumab met all three co-primary endpoints - - New
Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR - Both doses of investigational drug sarilumab met all three co-primary endpoints - - New data include major clinical response rates and ACR20 scores at 52 week
Read more →SNYSanofi and Lilly announce licensing agreement for Cialis (tadalafil) OTC - Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents - PARIS, France,
Sanofi and Lilly announce licensing agreement for Cialis (tadalafil) OTC - Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents - PARIS, France, and INDIANAPOLIS, May 28, 2014 Sanofi (EURONEXT: SAN and
Read more →SNYThe World s First, Large-Scale Dengue Vaccine Efficacy Study Successfully Achieved Its Primary Clinical Endpoint First available data demonstrated a 56% reduction of dengue disease cases in a study of more than 10,000 vo
The World s First, Large-Scale Dengue Vaccine Efficacy Study Successfully Achieved Its Primary Clinical Endpoint First available data demonstrated a 56% reduction of dengue disease cases in a study of more than 10,000 volunteers from Asia Initial safety data are consistent wit
Read more →SNYGenzyme to Resubmit Lemtrada TM Application for FDA Review Paris, France
Genzyme to Resubmit LemtradaTM Application for FDA Review Paris, France April 7, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to r
Read more →SNYFiling of the 2013 U.S. Form 20-F and French Document de R f rence containing the Annual Financial Report Paris, France
Filing of the 2013 U.S. Form 20-F and French Document de R f rence containing the Annual Financial Report Paris, France - March 7, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and i
Read more →SNYSanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus and Lantus SoloStar Paris, France
Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus and Lantus SoloStar Paris, France January 30, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( Lilly ) on January 30, 2014 in
Read more →SNYSanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial - Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints -
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial - Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints - - Sarilumab is the First Fully-Human Monoclonal Antibody Directed Agains
Read more →SNYSanofi successfully prices EUR 1 billion bond issue Paris, France
Sanofi successfully prices EUR 1 billion bond issue Paris, France - November 7, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of EUR 1 billion of notes, due 2023, bearing interest at an annual rate of 2.50%. The issue is draw
Read more →SNYData Show Sanofi s Lyxumia Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled - Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combin
Data Show Sanofi s Lyxumia Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled - Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin - Paris, France September 24, 2013 Sanofi (EUR
Read more →SNYEuropean Commission Approves Genzyme s Multiple Sclerosis Treatment Lemtrada (alemtuzumab) Follows Recent European Commission Approval of Multiple Sclerosis Treatment Aubagio (teriflunomide) Approvals Set t
European Commission Approves Genzyme s Multiple Sclerosis Treatment Lemtrada (alemtuzumab) Follows Recent European Commission Approval of Multiple Sclerosis Treatment Aubagio (teriflunomide) Approvals Set the Stage for Launches Throughout EU and Strongly Position Genzyme as
Read more →SNYSanofi Provides Update on Lixisenatide New Drug Application in U.S. Paris, France
Sanofi Provides Update on Lixisenatide New Drug Application in U.S. Paris, France September 12, 2013 Sanofi (EURONEXT: SAN and NYSE: SNY) announced today its decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S., which included early interim results from t
Read more →SNYHALF-YEAR FINANCIAL REPORT CONTENTS CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED STATEMENTS OF COMPREHENSIVE I
2013 HALF-YEAR FINANCIAL REPORT CONTENTS CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 CONSOLIDATED STATEMENTS OF CHANGES IN EQUI
Read more →SNYGenzyme Receives Positive CHMP Opinion for LEMTRADA (alemtuzumab) in Europe CHMP also Recommends NAS Designation for AUBAGIO (teriflunomide) Following Positive Opinion on Approval in March 2013 Positive Opi
Genzyme Receives Positive CHMP Opinion for LEMTRADA (alemtuzumab) in Europe CHMP also Recommends NAS Designation for AUBAGIO (teriflunomide) Following Positive Opinion on Approval in March 2013 Positive Opinions Set Stage for Introduction of Two New Genzyme Therapies for Mult
Read more →SNYSanofi Provides Update on Phase 3 Studies of Two Investigational Compounds Paris, France
Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds Paris, France - June 3, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studies of its investigational compounds iniparib and otamixaban respectively.
Read more →SNYCombined General Shareholder Meeting of
Combined General Shareholder Meeting of May 3, 2013 Shareholder approval of the financial statements for 2012 Dividend of 2.77 per share payable as of May 14, 2013 Nomination of a new director, Ms. Fabienne Lecorvaisier Paris, France - May 3, 2013 - Sanofi (EURONEXT : SAN et
Read more →SNYSanofi successfully prices USD 1.5 billion bond issue Paris, France
Sanofi successfully prices USD 1.5 billion bond issue Paris, France - April 4, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of USD 1.5 billion of notes denominated in US dollars, due April 10, 2018, bearing interest at an an
Read more →SNYEffect of Genzyme s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies In more than 70 percent of patients, disability scores improved or remained stable over three years More than 80 percen
Effect of Genzyme s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies In more than 70 percent of patients, disability scores improved or remained stable over three years More than 80 percent of patients treated with LEMTRADA did not receive a third course of tr
Read more →SNYSanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis - Phase 1b Data Presented at Late Breaking Session of 71 st Annual Meeting of the Amer
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis - Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology - Paris, France and Tarrytown, NY - March 2,
Read more →SNYGenzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease Paris, France
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Paris, France February 15, 2013 Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglust
Read more →SNYP RODUCT S ALES S TATEMENT , FOR THE P RODUCT S ALES M EASURING P ERIOD ENDED D ECEMBER 31, 2012 As called for under 5.4 of the Contingent Value Rights Agreement by and between Sanofi (formerly known as sanofi-aventis) a
PRODUCT SALES STATEMENT, FOR THE PRODUCT SALES MEASURING PERIOD ENDED DECEMBER 31, 2012 As called for under 5.4 of the Contingent Value Rights Agreement by and between Sanofi (formerly known as sanofi-aventis) and American Stock Transfer & Trust Company LLC dated as of March 3
Read more →SNYGenzyme and Isis Announce FDA Approval of KYNAMRO (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia Paris, France and Carlsbad, California
Genzyme and Isis Announce FDA Approval of KYNAMRO (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia Paris, France and Carlsbad, California, January 29, 2013 Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme, and Isis Phar
Read more →SNYSanofi s Chattem Acquires Over-the-Counter Antacid Rolaids Product acquisition further strengthens Consumer Healthcare Division of Sanofi US Paris, France
Sanofi s Chattem Acquires Over-the-Counter Antacid Rolaids Product acquisition further strengthens Healthcare Division of Sanofi US Paris, France January 7, 2013 Sanofi (EURONEXT : SAN and NYSE : SNY) today announced that its US Consumer Healthcare Division, Chattem, Inc., co
Read more →SNYMerial to Acquire Animal Health Division of Dosch Pharmaceuticals in India Paris, France
Merial to Acquire Animal Health Division of Dosch Pharmaceuticals in India Paris, France - December 20, 2012 - Merial, the Animal Health division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that Sanofi has entered into a binding agreement to acquire the animal hea
Read more →SNYZALTRAP (aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer Paris, France and Tarrytown, NY
ZALTRAP (aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Paris, France and Tarrytown, NY November 16, 2012 Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced th
Read more →SNYSanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine Additional data from Phase 2 studies to be presented at the A
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine Additional data from Phase 2 studies to be presented at the American Heart Association s Scientific Sessions 2012 Paris, France a
Read more →SNYNew data from ORIGIN Shows Lantus use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population Paris, France
New data from ORIGIN Shows Lantus use is about 3 times likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population Paris, France October 5, 2012 Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results from the landmark ORIGIN (Ou
Read more →SNYGenzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint Paris, France
Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Paris, France - October 2, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that ENGAGE, the first Phase 3 trial of its investigational oral therap
Read more →SNYFDA Approves Genzyme s AUBAGIO (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis Paris, France
FDA Approves Genzyme s AUBAGIO (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis Paris, France September 12, 2012 Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has a
Read more →SNYU.S. FDA Approves ZALTRAP (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal Cancer Paris, France and Tarrytown, NY
U.S. FDA Approves ZALTRAP (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal Cancer Paris, France and Tarrytown, NY August 3, 2012 Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the
Read more →SNYT A B L E O F C O N T E N T S 2012 HALF - YEAR FINANCIAL REPORT Translation of the French Language Original CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE
2012 HALF-YEAR FINANCIAL REPORT Translation of the French Language Original CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED ST
Read more →SNYSanofi Pasteur s 6-in-1 Pediatric Vaccine Hexaxim Receives Positive Opinion from European Medicines Agency - EMA scientific opinion opens the door for registration of Hexaxim in international markets outsid
Sanofi Pasteur s 6-in-1 Pediatric Vaccine Hexaxim Receives Positive Opinion from European - EMA scientific opinion opens the door for registration of Hexaxim in international markets - HexaximTM, the only fully-liquid, ready to use 6-in-1 pediatric vaccine to improve the standa
Read more →SNYLantus Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes Approximately 50 percent more patients on Lantus achieved target HbA 1c versus sitagliptin at study
Lantus Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes Approximately 50 percent more patients on Lantus achieved target HbA1c versus sitagliptin at study endpoint EASIE study findings published in The Lancet Paris, France J
Read more →SNYSignificant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM * (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with alemtuzumab in CA
Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif in Phase lll Trial treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement Paris
Read more →SNYPhase 3 Extension Study Highlights Long-term Safety and Efficacy in
For Immediate Release March 29, 2012 Media Contact Genzyme: Ingrid Esser 617-768-6699 Ingrid.esser@genzyme.com Media Contact Isis: Amy Blackley, Ph.D. 760-603-2772 (Media) Kristina Lemonidis 760-603-2490 (Investors) KYNAMRO (mipomersen sodium) Data Presented a
Read more →SNYSanofi to Acquire Pluromed, Inc., Expanding its Presence in Biosurgery - Sanofi to commercialize LeGoo a highly innovative FDA approved and CE marked gel that provides temporary blood vessel occlusion during surgery - Pa
Sanofi to Acquire Pluromed, Inc., Expanding its Presence in Biosurgery - Sanofi to commercialize LeGoo a highly innovative FDA approved and CE marked gel that provides temporary blood vessel occlusion during surgery - Paris, France - March 16, 2012 - Sanofi (EURONEXT: SAN and N
Read more →SNYGenzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant Paris, France
Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant Paris, France - March 1, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme today announced that Genzyme has begun shipping Fabrazyme (agalsidase beta) produced at its newly
Read more →SNYGenzyme Announces FDA Approval of Framingham Manufacturing Plant Paris, France
Genzyme Announces FDA Approval of Framingham Manufacturing Plant Paris, France - January 24, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, M
Read more →SNYGenzyme Announces European Approval of Framingham Manufacturing Plant Paris, France
Genzyme Announces European Approval of Framingham Manufacturing Plant Paris, France - January 18, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Framingham,
Read more →SNYSanofi Reports Positive Results for Once-daily Lyxumia (lixisenatide) in Combination with Lantus (insulin glargine) in Type 2 Diabetes Data from phase III GetGoal Duo 1 study show combination helped achieve
Sanofi Reports Positive Results for Once-daily Lyxumia (lixisenatide) in Combination with (insulin glargine) in Type 2 Diabetes Data from phase III GetGoal Duo 1 study show combination helped achieve HbA1c < 7.0% and significantly improved 2-h post-prandial glucose in uncontro
Read more →SNYStatement regarding authorization to purchase outstanding Contingent Value Rights (CVRs) Sanofi has obtained the necessary corporate authorizations to purchase any or all of the outstanding Contingent Value Rights ( CVR
Statement regarding authorization to purchase outstanding Contingent Value Rights (CVRs) Sanofi has obtained the necessary corporate authorizations to purchase any or all of the outstanding Contingent Value Rights ( CVR ). Sanofi intends for any purchases to be made through ope
Read more →SNYSanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia Paris, France and Tarrytown, NY
Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia Paris, France and Tarrytown, NY - November 10, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announc
Read more →SNYNet sales up 10.1% and Business net income 1 up 4.1% at CER 2 - Performance driven by growth platforms, Genzyme acquisition and cost savings - Q3 2011 Change on a reported basis Change at constant exchange rates 9 months
Net sales up 10.1% and Business net income1 up 4.1% at - Performance driven by growth platforms, Genzyme acquisition and cost savings - Q3 2011 Change on a reported basis Change at constant exchange rates 9 months 2011 Change on a reported basis Change at constant e
Read more →SNYInvestigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio (*) ) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity - Findings from Two-Year Pivotal Phase III TEMSO Trial Publishe
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio (*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity - Findings from Two-Year Pivotal Phase III TEMSO Trial Published today in The New England Journal of Medicine - Paris,
Read more →SNYSanofi successfully prices USD 1 billion bond issue Paris, France
Sanofi successfully prices USD 1 billion bond issue Paris, France - September 28, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of USD 1 billion of notes denominated in US dollars, due 2014, bearing interest at an annual rate
Read more →SNYFirst Half Condensed Consolidated Financial Statements for the six months ended
First Half Condensed Consolidated Financial Statements for the six months ended Operating and Financial Review and Recent Developments I CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS* 1 CONSOLIDATED BALANCE SHEETS ASSETS 1 CONSOLIDATED BALANCE SHEETS LIABILITIES
Read more →SNYEuropean Medicines Agency (EMA) confirms positive benefit-risk balance for Multaq - European Prescribing Information Updated to Ensure Multaq Use in Appropriate Paroxysmal and Persistent AF Patients - Paris
European Medicines Agency (EMA) confirms positive benefit-risk balance for Multaq Prescribing Information Updated to Ensure Multaq Use in Appropriate Paroxysmal and Persistent AF Patients - Paris, France - September 22, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced to
Read more →SNYLyxumia (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes - New phase III data from GetGoal-F1 study of once-daily lixisenatide support simpli
Lyxumia (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes III data from GetGoal-F1 study of once-daily lixisenatide support simplified treatment initiation - - Study results presented at the European Association
Read more →SNYSanofi Announces New Long Term Objectives Commenting on the Group s outlook, Sanofi CEO Christopher A. Viehbacher said : Sanofi has undergone an impressive transformation over the last two and a half years
Sanofi Announces New Long Term Objectives Commenting on the Group s outlook, Sanofi CEO Christopher A. Viehbacher said: Sanofi has undergone an impressive transformation over the last two and a half years and the patent cliff is now almost behind us. While 2012 will be impacted
Read more →SNYTable of Contents Free Translation of the French Language Original CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLI
Table of Contents Free Translation of the French Language Original CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 CONSOLIDATED BALANCE SHEETS ASSETS 2 CONSOLIDATED BALANCE SHEETS LIABILITIES AND EQUITY 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED STATEME
Read more →SNYSanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. - Strategic Divestiture to focus on Growth Platforms in the United States and Canada - Paris, France
Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. - Strategic Divestiture to focus on Growth Platforms in the United States and Canada - Paris, France - July 11, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the strategic dives
Read more →SNYSanofi Announces Positive Results from the All to Target Study Evaluating Two Lantus and Apidra Regimens versus Premixed Regimen -Data Presented at American Diabetes Association s 71 st Annual Scientific Se
Sanofi Announces Positive Results from the All to Target Study Evaluating Two Lantus and Apidra Regimens versus Premixed Regimen -Data Presented at American Diabetes Association s 71st Annual Scientific Sessions - France June 24, 2011 Sanofi (EURONEXT: SAN and NYSE: SNY) anno
Read more →SNYSanofi GetGo al Program on Lyxumia , as an Add-on to Basal Insulin, Shows Significant Positive Phase III Results - Reduction in HbA1c without Significant Increase in Hypoglycemia - Paris, France
Sanofi GetGoal Program on Lyxumia , as an Add-on to Basal Insulin, Shows Significant Positive Phase III Results - Reduction in HbA1c without Significant Increase in Hypoglycemia - Paris, France - May 31, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that new resu
Read more →SNYFDA Licenses Sanofi Pasteur s New Influenza Vaccine Delivered by Intradermal Microinjection Fluzone Intradermal (Influenza Virus Vaccine) first to offer an immunization option with 90 percent smaller needle
FDA Licenses Sanofi Pasteur s New Influenza Vaccine Delivered by Intradermal Microinjection Fluzone Intradermal (Influenza Virus Vaccine) first to offer an immunization option with 90 percent smaller needle Lyon, France May 10, 2011 Sanofi Pasteur, the vaccines division of S
Read more →SNYSanofi-aventis and Regeneron Report Positive Phase III Results with ZALTRAP (aflibercept) in Second-line Metastatic Colorectal Cancer Paris, France and Tarrytown, NY
Sanofi-aventis and Regeneron Report Positive Phase III Results with ZALTRAP (aflibercept) in Second-line Paris, France and Tarrytown, NY April 26, 2011 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the Pha
Read more →SNYSanofi-aventis Genzyme ISIS Media Contact : Media Contact : Media Contact : Marisol P ron Erin Emlock Amy Blackley, Ph.D. 33 1 53 77 45 02 (617) 768-6923 (760) 603-2772 Investor Contact : Investor Contact :
Sanofi-aventis Genzyme ISIS Media Contact : Media Contact : Media Contact : Marisol P ron Erin Emlock Amy Blackley, Ph.D. 33 1 53 77 45 02 (617) 768-6923 (760) 603-2772 Investor Contact : Investor Contact : Investor Contact : S bastien Martel Leah Monteiro Kristina Le
Read more →SNYSanofi-aventis Merck Media Contact : Media Contact : Jean-Marc Podvin David Caouette 33 1 53 77 44 50 1 (908) 423 34 61 Investor Contact : Investor Contact : S bastien Martel Carol Fergusson 33 1 53 77 45 45
Sanofi-aventis Merck Media Contact : Media Contact : Jean-Marc Podvin David Caouette 33 1 53 77 44 50 1 (908) 423 34 61 Investor Contact : Investor Contact : S bastien Martel Carol Fergusson 33 1 53 77 45 45 1 (908) 423 44 65 sanofi-aventis to maintain separ
Read more →SNYRATIO OF EARNINGS TO FIXED CHARGES The following table shows the ratios of our earnings to fixed charges for each of the five years ended
RATIO OF EARNINGS TO FIXED CHARGES The following table shows the ratios of our earnings to fixed charges for each of the five years ended December 31, 2010, computed on the basis of IFRS. Year ended December 31, 2010 2009 2008 2007 2006 16.3x 19.4x 13.8x 18.0x 12.2x r
Read more →SNYComposition of the Board of Directors of sanofi-aventis Paris, France
Composition of the Board of Directors Paris, France - March 9, 2011 - At its meeting held on March 9, 2011, the Board of Directors decided to propose the appointment of a new independent Director, Mrs. Suet-Fern Lee, during the General Shareholders meeting of May 6, 2011. As a
Read more →SNYSanofi-aventis Announces Positive Top-line Lixisenatide Phase III Results Paris, France
Sanofi-aventis Announces Positive Top-line Lixisenatide Phase III Results Paris, France - February 2, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that lixisenatide once-daily achieved primary efficacy endpoint and fewer hypoglycemias vs. exenatide The G
Read more →SNYJEVTANA (cabazitaxel) for Prostate Cancer Recommended for Approval in the European Union - Therapy provides significant survival benefit in second-line metastatic hormone- refractory prostate cancer in combination with p
JEVTANA (cabazitaxel) for Prostate Cancer Recommended for Approval in the European Union - Therapy provides significant survival benefit in second-line metastatic hormone- refractory prostate cancer in combination with prednisone or Paris, France - January 21, 2011 - Sanofi
Read more →SNYSanofi-aventis and Merck KGaA Sign Agreement to Jointly Investigate Novel Combinations Against Cancer - Research and development collaboration gives mutual access to innovative, targeted cancer compound combinations - Pa
Sanofi-aventis and Merck KGaA Sign Agreement to Jointly Investigate Novel Combinations Against Cancer development collaboration gives mutual access to innovative, targeted cancer compound combinations - Paris, France December 17, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE:
Read more →SNYSanofi-aventis announces Wayne Pisano s retirement and appoints Olivier Charmeil Senior Vice President Vaccines Paris, France
Sanofi-aventis announces Wayne Pisano s retirement and appoints Olivier Charmeil Senior Vice President Vaccines December 10, 2010 - Sanofi-aventis (EURONEXT : SAN and NYSE : SNY) announces the appointment of Olivier Charmeil as Senior Vice President, Sanofi Pasteur, the Vaccin
Read more →SNYSanofi Pasteur s Dengue Vaccine in Final Stage of Clinical Development - First Phase 3 study underway in Australia - Lyon, France
Sanofi Pasteur s Dengue Vaccine in Final Stage of Clinical Development - First Phase 3 study underway in Australia - Lyon, France November 4, 2010 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue va
Read more →SNYSanofi-aventis to Acquire BMP Sunstone creating a Strong Consumer Healthcare Platform in China Transaction accelerates consumer healthcare business in China, through BMP Sunstone s strong platform in the Cough & Cold and
Sanofi-aventis to Acquire BMP Sunstone creating a Strong Consumer Healthcare Paris, France and New York, New York October 28, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and BMP Sunstone Corporation (NASDAQ: BJGP) announced today that they have entered into a definitive
Read more →SNYSanofi-aventis Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Genzyme Paris, France
Sanofi-aventis Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Genzyme Paris, France October 20, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 197
Read more →SNYFinal Results from Phase II Study Confirm BSI-201 (Iniparib) Prolongs Survival in Metastatic Triple Negative Breast Cancer - Data presented at 35 th European Society for Medical Oncology (ESMO) Congress - Paris, France
Final Results from Phase II Study Confirm BSI-201 (Iniparib) Prolongs Survival in Metastatic Triple Negative Breast Cancer Data presented at 35th European Society for Medical Oncology Paris, France October 10, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully o
Read more →SNYSanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash - Genzyme s Unwillingness to Engage in Constructive Discussions Leads sanofi-aventis to Take Offer Directly to
Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash - Genzyme s Unwillingness to Engage in Constructive Discussions Leads sanofi-aventis to Take Offer Directly to Shareholders - - All-Cash Offer Provides Immediate and
Read more →SNYSanofi-aventis Comments on Injunctive Relief Hearing Regarding Lovenox Paris, France
Sanofi-aventis Comments on Injunctive Relief Hearing Regarding Paris, France Aug 26, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. District Court for the District of Columbia has denied the Company s request for preliminary injunctive relief a
Read more →SNYSanofi-aventis Announces Non-Binding Offer to Acquire Genzyme - $69 Per Share All-Cash Offer Represents Immediate and Certain Value and a Significant Premium for Genzyme Shareholders - - Transaction Would Help Genzyme Ac
Sanofi-aventis Announces Non-Binding - $69 Per Share All-Cash Offer Represents Immediate and Certain Value and a Significant Premium for Genzyme Shareholders - - Transaction Would Help Genzyme Achieve its Vision of Making a Positive Impact on the Lives of People with Serious
Read more →SNYTable of Contents Table of Contents Free Translation of the French Language Original Condensed half-year consolidated financial statements 2 Consolidated balance sheets Assets 2 Consolidated balance sheets Liabilities &
Table of Contents Free Translation of the French Language Original Condensed half-year consolidated financial statements 2 Consolidated balance sheets Assets 2 Consolidated balance sheets Liabilities & Equity 3 Consolidated income statements 4 Consolidated statements of com
Read more →SNYSanofi-aventis expresses concern over the approval of another version of enoxaparin sodium in the U.S. Paris, France
Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium in the U.S. France July 23, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on today s approval by the U.S. Food and Drug Administration (FDA) of another version of en
Read more →SNYJevtana (cabazitaxel) Injection Now Available in the U.S. - Jevtana plus prednisone is the first and only therapy approved for patients with metastatic hormone-refractory prostate cancer previously treated with docetaxel
(cabazitaxel) Injection Now Available in the U.S. - Jevtana plus prednisone is the first and only therapy approved for patients with metastatic hormone-refractory prostate cancer previously treated with docetaxel-based therapy - Paris, France July 19, 2010 Sanofi-aventis (EU
Read more →SNYSanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in Oncology - Small molecules could restore Tumor Cell Apoptosis by reactivating tumor suppressor functions of the p53 gene - Pa
Sanofi-aventis and US Biopharmaceutical Company Ascenta Sign License Agreement in Oncology - Small molecules could restore Tumor Cell Apoptosis by reactivating tumor suppressor functions of the p53 gene - Paris, France June 4, 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY
Read more →SNYChange in sanofi-aventis Executive Committee Paris, France
Change in sanofi-aventis Executive Paris, France - April 30, 2010 - Sanofi-aventis (EURONEXT : SAN ; NYSE : SNY) announced today that Laurence Debroux, Senior Vice President, Chief Strategic Officer and member of the Executive Committee, has decided to leave the Group to pursue
Read more →SNYSanofi-aventis Announces Court Decision Resolving Eloxatin U.S. Patent Litigation - Eloxatin Expected to Recover in the U.S. Market - Paris, France
Sanofi-aventis Announces Court Decision Eloxatin U.S. Patent Litigation Eloxatin Expected to Recover in the U.S. Market - Paris, France April 23, 2010 - Sanofi-aventis (EURONEXT:SAN and NYSE: SNY) announced today that Sun Pharmaceuticals will be required to cease selling its
Read more →SNYSanofi-aventis Announces Settlement of Eloxatin U.S. Patent litigation Paris, France
Sanofi-aventis Announces Settlement Eloxatin U.S. Patent litigation Paris, France April 1, 2010 - Sanofi-aventis (EURONEXT:SAN and NYSE: SNY) announced today that it has settled U.S. patent infringement suits related to generic versions of Eloxatin (oxaliplatin) with certain d
Read more →SNYMEDIA Sanofi-aventis Bristol-Myers Squibb Ingrid G rg-Armbrecht Carmel Hogan + 33 153-774-625 + 33 674-107-658 ingrid.goerg-armbrecht@sanofi-aventis.com carmel.hogan@bms.com INVESTORS S bastien Martel John Elicker + 33 1
MEDIA Sanofi-aventis Bristol-Myers Squibb Ingrid G rg-Armbrecht Carmel Hogan + 33 153-774-625 + 33 674-107-658 ingrid.goerg-armbrecht@sanofi-aventis.com carmel.hogan@bms.com INVESTORS S bastien Martel John Elicker + 33 153-774-545 (609) 252-4611 IR@sanofi-aventis.com j
Read more →SNYCAPITALIZATION AND INDEBTEDNESS The following table sets forth our current and long-term liabilities and total capitalization as of
CAPITALIZATION AND INDEBTEDNESS sets forth our current and long-term liabilities and total capitalization as of December 31, 2009. The financial information in this table was extracted from our consolidated financial statements as of and for the year ended December 31, 2009, pr
Read more →SNYSanofi Pasteur s A(H1N1) Vaccine HUMENZA * Recommended by European Medicines Agency Lyon, France
Sanofi Pasteur s A(H1N1) Vaccine by European Medicines Agency Lyon, France - February 19, 2010 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its adjuvanted A(H1N1) monovalent influenza vaccine, Humenza , has
Read more →SNYSanofi-aventis Signs Agreements to Establish New Consumer Healthcare Joint Venture in China with Minsheng Pharmaceutical Group - Sanofi-aventis Poised to Enter the Dynamic Consumer Healthcare Market in China - Paris, Fra
Sanofi-aventis Signs Agreements to Establish New Consumer Healthcare Joint in China with Minsheng Pharmaceutical - Sanofi-aventis Poised to Enter the Dynamic Consumer Healthcare Market in China - Paris, France - January 29, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY
Read more →SNYSanofi-aventis provides an R&D Pipeline update - CHMP Positive opinion for DuoPlavin in Cardiology - FDA Fast Track designation with Rolling Submission obtained for Cabazitaxel in Prostate Cancer - Discontinuation of Dev
Sanofi-aventis provides an Paris, France December 21, 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today an update of its R&D pipeline for four of its projects: DuoPlavin in cardiology, cabazitaxel in oncology, eplivanserin in insomnia and idrabiotaparinux in th
Read more →Competitive Position
How SNY ranks across every disease it competes inCompetitive Position is a premium feature
See how SNY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial